

# BIRCH, STEWART, KOLASCH & BIRCH, LLP

TERRELL C. BIRCH  
RAYMOND C. STEWART  
JOSEPH A. KOLASCH  
JAMES M. SLATTERY  
BERNARD L. SWEENEY\*  
MICHAEL K. MUTTER  
CHARLES GORENSTEIN  
GERALD M. MURPHY, JR.  
LEONARD R. SVENSSON  
TERRY L. CLARK  
ANDREW D. MEIKLE  
MARC S. WEINER  
JOE MCKINNEY MUNCY  
ROBERT J. KENNEY  
DONALD J. DALEY  
JOHN W. BAILEY  
JOHN A. CASTELLANO, III

OF COUNSEL:  
HERBERT M. BIRCH (1905-1996)  
ELLIOT A. GOLDBERG\*  
WILLIAM L. GATES\*  
EDWARD H. VALANCE  
RUPERT J. BRADY (RET)\*

\*ADMITTED TO A BAR OTHER THAN VA

INTELLECTUAL PROPERTY LAW  
8110 GATEHOUSE ROAD  
SUITE 500 EAST  
FALLS CHURCH, VA 22042-1210  
USA

(703) 205-8000

FAX: (703) 205-8050  
(703) 698-8590 (G IV)

e-mail: mailroom@bskb.com  
web: http://www.bskb.com

CALIFORNIA OFFICE  
650 TOWN CENTER DRIVE, SUITE 1120  
COSTA MESA, CA 92626-7125  
(714) 708-8555  
FAX: (714) 708-8565

GARY D. YACURA  
THOMAS S. AUCHTERLONIE  
MICHAEL R. CAMMARATA  
JAMES T. ELLER, JR.  
SCOTT L. LOWE  
MARY ANN CAPRIA  
MARK J. NUELLE, PH.D.  
DARIN E. BARTHOLOMEW\*  
D. RICHARD ANDERSON  
PAUL C. LEWIS  
W. KARL RENNER

REG. PATENT AGENTS:  
FREDERICK R. HANDREN  
ANDREW J. TELESZ, JR.  
MARYANNE LIOTTA, PH.D.  
MAKI HATSUMI  
MIKE S. RYU  
CRAIG A. McROBBIE  
GARTH M. DAHLEN, PH.D.  
LAURA C. LUTZ  
ROBERT E. GOOZNER, PH.D.  
HYUNG N. SOHN  
MATTHEW J. LATTIG  
ALAN PEDERSEN-GILES

Date: December 15, 1999  
Docket No.: 1781-180P

## BOX PATENT APPLICATION

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

Transmitted herewith for filing is a patent application claiming priority under 35 U.S.C. § 119(e) of Provisional Application No. 60/112,499 filed on December 16, 1998.

Inventor(s): CHAN, Lily; CHUNG, Maxey Ching Ming; LIM, Renee Lay Hong

For: BACTERIAL-DERIVED MOLECULES AND THERAPEUTIC AND DIAGNOSTIC USES THEREFOR

Enclosed are:

- ☒ A specification consisting of Fifty-Six (56) pages
- ☒ Nine (9) sheet(s) of formal drawings
- ☐ An assignment of the invention
- ☐ Certified copy of Priority Document(s)
- ☒ Executed Declaration (☒ Original ☒ Photocopy)
- ☐ A statement (☐ original ☐ photocopy) to establish small entity status under 37 C.F.R. § 1.9 and 37 C.F.R. § 1.27
- ☒ Preliminary Amendment
- ☐ Information Disclosure Statement, PTO-1449 and reference(s)

- ☐ Other:
- ☒ Amend the specification by inserting before the first line the sentence:

--This application claims priority on provisional Application No. 60/112,499 filed on December 16, 1998, the entire contents of which are hereby incorporated by reference.--

The filing fee has been calculated as shown below:

			LARGE ENTITY	SMALL ENTITY
BASIC FEE			\$760.00	\$380.00
	NUMBER FILED	NUMBER EXTRA	RATE FEE	RATE FEE
<b>TOTAL CLAIMS</b>	29- 20 =	9	X 18 = \$162.00	X 9 = \$0.00
<b>INDEPENDENT CLAIMS</b>	8- 3 =	5	x 78 = \$390.00	X 39 = \$0.00
<input checked="" type="checkbox"/> MULTIPLE DEPENDENT CLAIMS PRESENTED			+ \$260.00	+ \$130.00
<b>TOTAL</b>			\$1,572.00	\$0.00

- ☒ A check in the amount of \$1,612.00 to cover the filing fee and recording fee (if applicable) is enclosed.
- ☐ Please charge Deposit Account No. 02-2448 in the amount of \$0.00. A triplicate copy of this transmittal form is enclosed.
- ☒ Please send correspondence to:

BIRCH, STEWART, KOLASCH & BIRCH, LLP **or** Customer No. 2292  
P.O. Box 747  
Falls Church, VA 22040-0747  
Telephone: (703) 205-8000


Docket No. 1781-180P

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. §§ 1.16 or 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By



Gerald M. Murphy, Jr., #28,977

GMM/MAA/sas

P.O. Box 747  
Falls Church, VA 22040-0747  
(703) 205-8000

Attachments

(Rev. 09/15/99)

PATENT  
1781-180P

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicants: CHAN, Lily et al  
Serial No.: New Group: Unknown  
Filed: December 15, 1999 Examiner: Unknown  
For: BACTERIAL-DERIVED MOLECULES AND THERAPEUTIC AND  
DIAGNOSTIC USES THEREFOR

**PRELIMINARY AMENDMENT**

Assistant Commissioner for Patents  
Box Patent Application  
Washington, D.C. 20231

December 15, 1999

Sir:

The following preliminary amendments and remarks are respectfully  
submitted in connection with the above-identified application.

**IN THE CLAIM:**

**CLAIM 18:** Line 1, change "any one of claims 1 to 9" to --claim 1--

**CLAIM 22:** Lines 1 and 2, change "any one of claims 1 to 9" to  
--claim 1--

\*\*\*\*\* R E M A R K \*\*\*\*\*

The above amendment to the claims is merely to delete the improper multiple dependencies and place the application into better form prior to examination.


Favorable action on the above-identified application is respectfully requested.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. §1.16 or under 37 C.F.R. §1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By

  
GERALD M. MURPHY, JR.  
Reg. No. 28,977  
P.O. Box 747  
Falls Church, VA 22040-0747  
(703) 205-8000

GMM/sas

## BACTERIAL-DERIVED MOLECULES AND THERAPEUTIC AND DIAGNOSTIC USES THEREFOR

### FIELD OF THE INVENTION

The present invention relates generally to molecules derived from a *Mycobacterium* species  
5 and recombinant, synthetic, derivative, homologue and analogue forms of said molecules. The  
molecules of the present invention are useful in diagnostic assays for *Mycobacterium* in  
biological and environmental samples. The present invention is particularly directed to  
molecules derived from *Mycobacterium tuberculosis* and related organisms and even more  
particularly to recombinant forms of these molecules or synthetic, derivative, homologue or  
10 analogue forms thereof and their use in diagnostic and therapeutic protocols for tuberculosis or  
other disease conditions associated with *M. tuberculosis* or related organisms.

### BACKGROUND OF THE INVENTION

Bibliographic details of the publications numerically referred to in this specification are  
collected at the end of the description.

15 Bacterial infection represents a major cause of mortality and morbidity in human and other  
animal populations. One important group of bacteria are the mycobacteria. The mycobacteria  
are defined on the basis of a distinctive staining property conferred by their lipid-rich cell  
walls. The mycobacteria are relatively impermeable to various basic dyes but once stained,  
they retain dyes with tenacity. The mycobacteria have been referred to as "acid-fast" bacteria  
20 since they resist decolorization with acidified organic solvents (1). Mycobacteria range from  
widespread innocuous inhabitants of soil and water to organisms responsible for devastating  
and chronic diseases notably in tuberculosis and leprosy caused by *Mycobacterium  
tuberculosis* and *Mycobacterium leprae*, respectively.

Leprosy involves infection in skin tissue and can lead to disfigurement. Tuberculosis is  
25 generally confined to internal organs. Although both leprosy and tuberculosis were largely  
controlled by chemical intervention and improvements in living conditions, tuberculosis is  
now re-emerging as a major health problem. On an annual basis, reportedly between 2 and 3  
million people die from tuberculosis, mostly in developing countries (2).

Conventional diagnostic tests for tuberculosis include chest X-ray, detecting the presence of acid-fast bacilli in clinical specimens and the skin test using tuberculin PPD (Purified Protein Derivative) [3]. However, these procedures are time intensive, frequently the results are ambiguous and X-ray machines are expensive and generally not portable enough for use in  
5 developing countries.

Nucleic acid probes can be used in a polymerase chain reaction (PCR) to specifically detect a mycobacterial infection, but require complex equipment, highly skilled staff and are too expensive for the developing countries (4). Rapid serological diagnostic tests are available on an ELISA or "strip" format which uses antigen(s) to detect antibody in sera (5).  
10 However, currently there is no satisfactory test for tuberculosis. A majority of *M. tuberculosis* antigens studied to date have homology with analogues proteins of other microorganisms that may or may not be pathogenic; resulting in cross-reactivity of these antigens to reactive serum antibodies in patients with inactive TB or nontuberculous infections (6). Hence, positive test results produced by these known antigens are generally  
15 unreliable and supplementary tests are required to confirm the presence of the tuberculosis infection.

In work leading up to the present invention, the inventors sought to use recombinant molecules from *M. tuberculosis* in the development of a highly specific and sensitive diagnostic test for tuberculosis. The same or similar molecules are also proposed for use as therapeutic agents  
20 for the treatment of tuberculosis.

## SUMMARY OF THE INVENTION

Throughout this specification, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element or integer or group of elements or integers but not the exclusion of any  
25 other element or integer or group of elements or integers.

The subject specification contains nucleotide and amino acid sequence information prepared using the programme PatentIn Version 2.1, presented herein after the bibliography. Each

nucleotide or amino acid sequence is identified in the sequence listing by the numeric indicator <210> followed by the sequence identifier (e.g. <210> 1, <210> 2, etc). The length, type of sequence (DNA, protein (PRT), etc) and source organism for each nucleotide or amino acid sequence are indicated by information provided in the numeric indicator fields  
5 <211>, <212> and <213>, respectively. Nucleotide and amino acid sequences referred to in the specification are defined by the information provided in numeric indicator field <400> followed by the sequence identifier (eg. <400> 1, <400> 2, etc).

One aspect of the present invention provides an isolated polypeptide or a derivative, homologue, analogue or functional equivalent thereof wherein said polypeptide is obtainable  
10 from a species of *Mycobacterium* and which polypeptide is immunointeractive with sera from a human, animal or avian species exposed to said species of *Mycobacterium* or its relative or antigenic parts thereof but which polypeptide is substantially not immunointeractive with sera from a human, animal or avian species not prior exposed to said species of *Mycobacterium* or its relative or its antigenic parts.

15 Another aspect of the present invention is directed to an isolated polypeptide or a derivative, homologue, analogue or functional equivalent thereof wherein said polypeptide is obtainable from *M. tuberculosis* or a related organism and which polypeptide is immunointeractive with sera from a human previously exposed to *M. tuberculosis* or an antigenic extract therefrom but is substantially not immunointeractive with human sera not previously exposed to *M.*  
20 *tuberculosis* or a antigenic extract thereof.

Yet another aspect of the present invention relates to an isolated polypeptide obtainable from *M. tuberculosis* or related organism or a derivative, homologue, analogue or chemical equivalent of said polypeptide which polypeptide is immunointeractive with sera from a human patient with active pulmonary or extra-pulmonary tuberculosis but is substantially not  
25 immunointeractive with sera from a subject not previously infected with *M. tuberculosis* or sera from a subject who otherwise has no immunological memory for said polypeptide or antigenic derivatives thereof.

Still yet another aspect of the present invention provides a polypeptide having a molecular weight selected from about 5 kDa to about 100 kDa or a derivative, homologue, analogue or



functional equivalent thereof said polypeptide obtainable from *M. tuberculosis* and wherein polypeptide is immunointeractive with sera from a patient with active pulmonary or extra-pulmonary tuberculosis but substantially not immunointeractive with sera from a subject who does not have active pulmonary or extra-pulmonary tuberculosis.

- 5 In still yet another aspect of the present invention there is provided a polypeptide having a molecular weight selected from about 10 to 20 kDa, 28 to 38 kDa, 38 to 48 kDa, 53 to 63 kDa and 55 to 65 kDa or a derivative, homologue, analogue or functional equivalent thereof said polypeptide obtainable from *M. tuberculosis* and wherein polypeptide is immunointeractive with sera from a patient with active pulmonary or extra-pulmonary tuberculosis but substantially not immunointeractive with sera from a subject who does not have active pulmonary or extra-pulmonary tuberculosis.

Yet a further aspect of the present invention provides a polypeptide comprising an amino acid sequence selected from <400>2, <400>4, <400>6, <400>8, <400>10 or an amino acid sequence having at least 60% similarity to any one of said sequences.

- 15 Still yet a further aspect of the present invention provides a polypeptide encoded by a nucleotide sequence selected from <400>1, <400>3, <400>5, <400>7, <400>9 or an nucleotide sequence having at least 60% similarity to any one of said sequences or a nucleotide sequence capable of hybridizing to any one of said sequences under low stringency conditions at 42°C.

- 20 Another aspect of the present invention contemplates a method of isolating a polypeptide from *Mycobacterium* species said method comprising culturing cells of said *Mycobacterium* species in a growth medium to increase the number of cells to a sufficient population, harvesting said cells and subjecting said cells to protein extraction techniques to extract protein from said cells, fractionating the extracted protein and subjecting said protein to binding analysis with antibodies to said *Mycobacterium* species or antigenic portions thereof and isolating the polypeptides to which antibodies interact.

Yet another aspect of the present invention is directed to an isolated nucleic acid molecule comprising a sequence of nucleotides encoding or complementary to a sequence encoding a

polypeptide obtainable from a species of *Mycobacterium* and which polypeptide is immunointeractive with sera from a human, animal or avian species exposed to said species of *Mycobacterium* or its relative or antigenic parts thereof but which polypeptide is substantially not immunointeractive with sera from a human, animal or avian species not prior exposed to said species of *Mycobacterium* or its relative or its antigenic parts.

Another aspect of the present invention contemplates a method for detecting the presence of *M. tuberculosis* such as in a patient suffering from tuberculosis said method comprising contacting a biological sample from a patient or subject with an antibody specific for a polypeptide from said *M. tuberculosis* and detecting a complex between said polypeptide and said antibody.

Yet another aspect of the present invention provides a method for detecting the presence of *M. tuberculosis* such as in a patient suffering from tuberculosis said method comprising contacting a sera sample from a patient or subject with a polypeptide from *M. tuberculosis* and detecting a complex between said polypeptide and an antibody in said sera.

Still yet another aspect of the present invention provides an assay device for *M. tuberculosis* comprising a solid support having immobilized thereon one or more polypeptides obtainable from *M. tuberculosis* or derivatives, homologues, analogues or antigenic equivalents thereof and a portion of said solid support adapted for receiving a sample from a human subject to be tested wherein said sample would contain an antibody specific for said *M. tuberculosis* polypeptide if said subject has been exposed to *M. tuberculosis* wherein upon contact between the antibody from the subject and the immobilized polypeptide, a complex forms and said complex is detected by an anti-human immunoglobulin labelled with a reporter molecule.

#### BRIEF DESCRIPTION OF THE FIGURES

**Figure 1** is a diagrammatic representation of the strategy for the isolation and expression of *M. tuberculosis* protein antigens.

**Figure 2** is a photographic representation showing (A) gel purified and concentrated *M. tuberculosis* protein bands (B.1, 2, 3, 4, 5, 6, 8, 9, 10) blotted onto PVDF membrane and were then excised for N-terminal sequencing; (B) concentrated *M. tuberculosis* protein bands were

blotted onto nitrocellulose membrane and immuno-screened using pooled normal (N) and active (A) sera, respectively. Positive bands (arrows) were observed with A but not with N.

**Figure 3** is a representation showing the results of homology search against the GenBank protein sequence databases. Proteins showing the highest homology to the *M. tuberculosis* protein bands are as shown.

**Figure 4** is a photographic representation of Western blot screening of recombinant *M. tuberculosis* antigens. (A) Arrows indicate the position of the recombinant antigens on the membrane. M=Kaleidoscope protein marker and H=strip probed with anti-RGSHis, C= a positive control of strips probed with known human serum reactive to the specific recombinant antigen. (B) Reactivity is estimated based on the intensity of the band.

**Figure 5** is a representation of the percentage of reactivity of recombinant TB antigens against different sera panels. A known 38kDa antigen (7, 8) of *M. tuberculosis* was included in the screening. The gene (GeneBank Accession # M30046) for this antigen was cloned, expressed in pQE30 and partially purified. Also shown are the percentages of reactivity of sera samples detected by a commercially available rapid TB diagnostic kit from ICT (Amrad).

**Figure 6** is a graphical representation of a result from a Western screen using sera from normal individuals or patients with extrapulmonary tuberculosis, pulmonary tuberculosis and inactive tuberculosis.

**Figure 7** is a graphical representation showing the percentage of reactivity for various combinations of these recombinant antigens against the inactive, active (pulmonary) and active (extra-pulmonary) sera panels respectively.

**Figure 8** is a graphical representation showing the comparison of reactivity against the different sera panel for the combination of all the recombinant TB antigens compared to the ICT TB diagnostic kit. The graph shows that the percentage of reactivity for the active sera panel (pulmonary and extra-pulmonary) is higher than that observed for the kit.

**Figure 9** is a graphical representation showing that the combination of antigens (B.6 + B.10 + MMP + 38 kDa) gave a sensitivity (60-70%) higher than that observed for the ICT kit (50%).

A summary of the sequence listing is shown below:

Sequence	Sequence Identity No.
Nucleotide sequence of antigen B.4	<400>1
Amino acid sequence of antigen B.4	<400>2
Nucleotide sequence of antigen B.6	<400>3
Amino acid sequence of antigen B.6	<400>4
Nucleotide sequence of antigen B.10	<400>5
Amino acid sequence of antigen B.10	<400>6
Nucleotide sequence of antigen MMP	<400>7
Amino acid sequence of antigen MMP	<400>8
Nucleotide sequence of antigen C17	<400>9
Amino acid sequence of antigen C17	<400>10

## DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention is predicated in part on the identification of molecules from *Mycobacterium* species which are immunointeractive with antigen-specific molecules from humans, animals or birds which have been infected with the *Mycobacterium* species or its relative or extracts thereof or following administration to humans, animals or birds the molecule itself or in combination with a mixture of molecules. Detection of the molecules from *Mycobacterium* species or antibodies thereto is indicative of the presence of the particular species of *Mycobacterium* and hence has both diagnostic and therapeutic implications.

Accordingly, one aspect of the present invention provides an isolated polypeptide or a derivative, homologue, analogue or functional equivalent thereof wherein said polypeptide is obtainable from a species of *Mycobacterium* and which polypeptide is immunointeractive with sera from a human, animal or avian species exposed to said species of *Mycobacterium* or its relative or antigenic parts thereof but which polypeptide is substantially not immunointeractive with sera from a human, animal or avian species not prior exposed to said species of *Mycobacterium* or its relative or its antigenic parts.

For the purposes of exemplifying the present invention, the preferred species of *Mycobacterium* is *M. tuberculosis*. However, the present invention also extends to its relatives, *Mycobacterium bovis* and *Mycobacterium africanum*. In addition, the present invention further contemplates other mycobacteria including but not limited to *Mycobacterium avium*, *Mycobacterium microti*, *Mycobacterium leprae*, *Mycobacterium lepraemurium*, *Mycobacteria paratuberculosis*, *Mycobacterium ulcerans*, *Mycobacterium marinum*, *Mycobacterium smegmatis*, *Mycobacterium intracellulare*, *Mycobacterium xenopi*, *Mycobacterium chelonae*, *Mycobacterium fortuitum*, *Mycobacterium farcinogenes*, *Mycobacterium flavum*, *Mycobacterium haemophilum*, *Mycobacterium kansasii*, *Mycobacterium phlei*, *Mycobacterium scrofulaceum*, *Mycobacterium senegalense*, *Mycobacterium simiae*, *Mycobacterium thermoresistibile*, and *Mycobacterium xenopi*.

Accordingly, in a preferred embodiment, the present invention is directed to an isolated polypeptide or a derivative, homologue, analogue or functional equivalent thereof wherein

said polypeptide is obtainable from *M. tuberculosis* or a related organism and which polypeptide is immunointeractive with sera from a human previously exposed to *M. tuberculosis* or an antigenic extract therefrom but is substantially not immunointeractive with human sera not previously exposed to *M. tuberculosis* or a antigenic extract thereof.

- 5 In the comparison to human sera not previously exposed to *M. tuberculosis*, this does not exclude sera from subjects previously exposed to other species of *Mycobacterium* or other genera having biochemical or genetic but not epidemeological properties related to *M. tuberculosis*.

10 The sera preferably contains antibodies to the polypeptide of the present invention. The present invention extends, however, to other antigen-specific molecules or components of the immune system having antigen specificity including but not limited to cells carrying surface immunoglobulins specific to the polypeptide and T-cell derived antigen binding molecules (TABMs).

15 Preferably, the immunointeraction is an interaction between an antibody in the sera of a person previously exposed to *M. tuberculosis* or a related organism or an antigen containing extract therefrom and the polypeptide or its antigenic derivatives from *M. tuberculosis*. The term "related" in this context means another species of *Mycobacterium* or strain of *M. tuberculosis* which is associated with a similar disease as caused or exacerbated by *M. tuberculosis*.

20 Generally, a person "previously" exposed to *M. tuberculosis* or its antigen extract, is a person exhibiting immunological memory of the interaction and, hence, carrying antibodies in the sera to an antigen of *M. tuberculosis*. Conveniently, the sera are from patients with active pulmonary or extra-pulmonary tuberculosis.

25 As stated above, reference to a relative to *M. tuberculosis* includes various strains of *M. tuberculosis* as well as different species of *Mycobacterium* which contain the same polypeptide or an antigenically related polypeptide. Examples of related species include *M. bovis* and *M. africanum*. Such related strains or species would induce or be associated with similar disease conditions induced by *M. tuberculosis*.

Accordingly, another aspect of the present invention provides an isolated polypeptide

obtainable from *M. tuberculosis* or related organism or a derivative, homologue, analogue or chemical equivalent of said polypeptide which polypeptide is immunointeractive with sera from a human patient with active pulmonary or extra-pulmonary tuberculosis but is substantially not immunointeractive with sera from a subject not previously infected with *M. tuberculosis* or sera from a subject who otherwise has no immunological memory for said polypeptide or antigenic derivatives thereof.

In a preferred embodiment, the polypeptides of the present invention from *M. tuberculosis* range in molecular weight from about 5 kDa to about 100 kDa. More preferably, the polypeptides have a molecular weight range of from about 10 to 20 kDa, 28 to 38 kDa, 38 to 48 kDa, 53 to 63 kDa and 55 to 65 kDa.

In a most preferred embodiment, the molecular weight of the polypeptides are selected from  $16\pm3$ ,  $33\pm3$ ,  $38\pm3$ ,  $55\pm3$  and  $56\pm3$  kDa.

Accordingly, another aspect of the present invention is directed to a polypeptide having a molecular weight selected from about 5 kDa to about 100 kDa or a derivative, homologue, analogue or functional equivalent thereof said polypeptide obtainable from *M. tuberculosis* and wherein the polypeptide is immunointeractive with sera from a patient with active pulmonary or extra-pulmonary tuberculosis but substantially not immunointeractive with sera from a subject who does not have active pulmonary or extra-pulmonary tuberculosis.

More particularly, the present invention provides a polypeptide having a molecular weight selected from  $16\pm3$ ,  $33\pm3$ ,  $38\pm3$ ,  $55\pm3$  and  $56\pm3$  kDa or a derivative, homologue, analogue or functional equivalent thereof said polypeptide obtainable from *M. tuberculosis* and wherein polypeptide is immunointeractive with sera from a patient with active pulmonary or extra-pulmonary tuberculosis but substantially not immunointeractive with sera from a subject who does not have active pulmonary or extra-pulmonary tuberculosis.

The present invention is particularly exemplified in relation to *Mycobacterium* antigens B.4, B.6, B.10, MMP and C17 having amino acid sequences and corresponding nucleotide sequences as set forth in <400>1, <400>3, <400>5, <400>7, <400>9 respectively.

Accordingly, another aspect of the present invention provides a polypeptide comprising an amino acid sequence selected from <400>2, <400>4, <400>6, <400>8, <400>10 or an amino acid sequence having at least 60% similarity to any one of said sequences.

Yet a further aspect of the present invention provides a polypeptide encoded by a nucleotide sequence selected from <400>1, <400>3, <400>5, <400>7, <400>9 or an amino acid sequence having at least 60% similarity to any one of said sequences or a nucleotide sequence capable of hybridizing to any one of said sequences under low stringency conditions at 42°C.

Even yet a further aspect of the present invention provides a nucleotide sequence selected from <400>1, <400>3, <400>5, <400>7, <400>9 or an amino acid sequence having at least 60% similarity to any one of said sequences or a nucleotide sequence capable of hybridizing to any one of said sequences under low stringency conditions at 42°C.

The term "similarity" as used herein includes exact identity between compared sequences at the nucleotide or amino acid level. Where there is non-identity at the nucleotide level, "similarity" includes differences between sequences which result in different amino acids that are nevertheless related to each other at the structural, functional, biochemical and/or conformational levels. Where there is non-identity at the amino acid level, "similarity" includes amino acids that are nevertheless related to each other at the structural, functional, biochemical and/or conformational levels. In a particularly preferred embodiment, nucleotide and sequence comparisons are made at the level of identity rather than similarity.

Any number of programs are available to compare nucleotide and amino acid sequences. Preferred programs have regard to an appropriate alignment. One such program is Gap which considers all possible alignment and gap positions and creates an alignment with the largest number of matched bases and the fewest gaps. Gap uses the alignment method of Needleman and Wunsch (19). Gap reads a scoring matrix that contains values for every possible GCG symbol match. GAP is available on ANGIS (Australian National Genomic Information Service) at website <http://mell1.angis.org.au>.

Reference herein to a low stringency at 42°C includes and encompasses from at least about 1% v/v to at least about 15% v/v formamide and from at least about 1M to at least about 2M salt for hybridisation, and at least about 1M to at least about 2M salt for washing conditions.



Alternative stringency conditions may be applied where necessary, such as medium stringency, which includes and encompasses from at least about 16% v/v to at least about 30% v/v formamide and from at least about 0.5M to at least about 0.9M salt for hybridisation, and at least about 0.5M to at least about 0.9M salt for washing conditions, or  
5 high stringency, which includes and encompasses from at least about 31% v/v to at least about 50% v/v formamide and from at least about 0.01M to at least about 0.15M salt for hybridisation, and at least about 0.01M to at least about 0.15M salt for washing conditions. In general, washing is carried out  $T_m = 69.3 + 0.41 (G+C)\%$  (17). However, the  $T_m$  of a duplex DNA decreases by 1°C with every increase of 1% in the number of mismatch base  
10 pairs (18).

The present invention also provides genetic constructs comprising nucleic acid molecules encoding the *Mycobacterium* antigens as well as cells transformed with same. Examples of such cells include *Mycobacterium* cells, *E. coli*, insect cells, yeast cells, mammalian cells and plant cells.

15 The term "derivative" includes mutants, fragments and parts of the polypeptide of the present invention including single and multiple amino acid substitutions, additions and/or deletions to the naturally occurring amino acid sequences.

Preferably, the derivative is an antigenic fragment of the subject polypeptide meaning it contains an epitope required for an antibody in the sera of a patient with active pulmonary or  
20 extra-pulmonary tuberculosis to bind to the antigenic fragment.

A homologue includes functionally, structurally or stereochemically similar polypeptides from other species of *Mycobacterium* or other genera of bacteria. A homologue as contemplated herein includes a mimotope. The use of mimotopes is quite useful in competing with *Mycobacterium* polypeptide antigens for binding to antibodies. This competition may then be  
25 used to determine the concentration of polypeptides.

Analogues and mimetics include molecules which contain non-naturally occurring amino acids and which do not contain amino acids but nevertheless behave functionally the same as the polypeptide. Natural product screening is one useful strategy for identifying analogues

and mimetics. Natural product screening involves screening environments such as bacteria, plants, riverbeds, seabeds, aquatic environments, coral and antarctic or arctic environments for naturally occurring molecules which mimic, agonise or antagonise the function of the *Mycobacterium* polypeptide of the present invention.

- 5 Chemical libraries may also be screened for synthetic mimetics, agonists, antagonists or chemical analogues of the subject polypeptides.

Analogues of the subject peptides contemplated herein also include modifications to side chains, incorporation of unnatural amino acids and/or their derivatives during peptide synthesis and the use of crosslinkers and other methods which impose conformational  
10 constraints on the peptide molecule or their analogues.

Examples of side chain modifications contemplated by the present invention include modifications of amino groups such as by reductive alkylation by reaction with an aldehyde followed by reduction with  $\text{NaBH}_4$ ; amidination with methylacetimidate; acylation with acetic anhydride; carbamoylation of amino groups with cyanate; trinitrobenzylation of amino  
15 groups with 2, 4, 6-trinitrobenzene sulphonic acid (TNBS); acylation of amino groups with succinic anhydride and tetrahydrophthalic anhydride; and pyridoxylation of lysine with pyridoxal-5-phosphate followed by reduction with  $\text{NaBH}_4$ .

The guanidine group of arginine residues may be modified by the formation of heterocyclic condensation products with reagents such as 2,3-butanedione, phenylglyoxal and glyoxal.

- 20 The carboxyl group may be modified by carbodimide activation *via* O-acylisourea formation followed by subsequent derivitisation, for example, to a corresponding amide.

Sulphydryl groups may be modified by methods such as carboxymethylation with iodoacetic acid or iodoacetamide; performic acid oxidation to cysteic acid; formation of a mixed disulphides with other thiol compounds; reaction with maleimide, maleic anhydride or other  
25 substituted maleimide; formation of mercurial derivatives using 4-chloromercuribenzoate, 4-chloromercuriphenylsulphonic acid, phenylmercury chloride, 2-chloromercuri-4-nitrophenol

and other mercurials; carbamoylation with cyanate at alkaline pH.

Tryptophan residues may be modified by, for example, oxidation with N-bromosuccinimide or alkylation of the indole ring with 2-hydroxy-5-nitrobenzyl bromide or sulphenyl halides. Tyrosine residues on the other hand, may be altered by nitration with tetranitromethane to form a 3-nitrotyrosine derivative.

Modification of the imidazole ring of a histidine residue may be accomplished by alkylation with iodoacetic acid derivatives or N-carbethoxylation with diethylpyrocarbonate.

Examples of incorporating unnatural amino acids and derivatives during peptide synthesis include, but are not limited to, use of norleucine, 4-amino butyric acid, 4-amino-3-hydroxy-5-phenylpentanoic acid, 6-aminohexanoic acid, t-butylglycine, norvaline, phenylglycine, ornithine, sarcosine, 4-amino-3-hydroxy-6-methylheptanoic acid, 2-thienyl alanine and/or D-isomers of amino acids. A list of unnatural amino acid contemplated herein is shown in Table 1.

TABLE 1

Non-conventional amino acid	Code	Non-conventional amino acid	Code
$\alpha$ -aminobutyric acid	Abu	L-N-methylalanine	Nmala
$\alpha$ -amino- $\alpha$ -methylbutyrate	Mgab	L-N-methylarginine	Nmarg
aminocyclopropane- carboxylate	Cpro	L-N-methylasparagine	Nmasn
aminoisobutyric acid	Aib	L-N-methylaspartic acid	Nmasp
aminonorbornyl-	Norb	L-N-methylcysteine	Nmcys
carboxylate		L-N-methylglutamine	Nmgln
cyclohexylalanine	Chexa	L-N-methylglutamic acid	Nmglu
cyclopentylalanine	Cpen	L-N-methylhistidine	Nmhis
D-alanine	Dal	L-N-methylisoleucine	Nmile
		L-N-methylleucine	Nmleu

	D-arginine	Darg	L-N-methyllysine	Nmlys
	D-aspartic acid	Dasp	L-N-methylmethionine	Nmmet
	D-cysteine	Dcys	L-N-methylnorleucine	Nmnle
	D-glutamine	Dgln	L-N-methylnorvaline	Nmnva
5	D-glutamic acid	Dglu	L-N-methylornithine	Nmorn
	D-histidine	Dhis	L-N-methylphenylalanine	Nmphe
	D-isoleucine	Dile	L-N-methylproline	Nmpro
	D-leucine	Dleu	L-N-methylserine	Nmser
	D-lysine	Dlys	L-N-methylthreonine	Nmthr
10	D-methionine	Dmet	L-N-methyltryptophan	Nmtrp
	D-ornithine	Dorn	L-N-methyltyrosine	Nmtyr
	D-phenylalanine	Dphe	L-N-methylvaline	Nmval
	D-proline	Dpro	L-N-methylethylglycine	Nmetg
	D-serine	Dser	L-N-methyl-t-butylglycine	Nmtbug
15	D-threonine	Dthr	L-norleucine	Nle
	D-tryptophan	Dtrp	L-norvaline	Nva
	D-tyrosine	Dtyr	$\alpha$ -methyl-aminoisobutyrate	Maib
	D-valine	Dval	$\alpha$ -methyl- $\gamma$ -aminobutyrate	Mgabv
	D- $\alpha$ -methylalanine	Dmala	$\alpha$ -methylcyclohexylalanine	Mchexa
20	D- $\alpha$ -methylarginine	Dmarg	$\alpha$ -methylcyclopentylalanine	Mcpen
	D- $\alpha$ -methylasparagine	Dmasn	$\alpha$ -methyl- $\alpha$ -naphthylalanine	Manap
	D- $\alpha$ -methylaspartate	Dmasp	$\alpha$ -methylpenicillamine	Mpen
	D- $\alpha$ -methylcysteine	Dmcys	N-(4-aminobutyl)glycine	Nglu
	D- $\alpha$ -methylglutamine	Dmgln	N-(2-aminoethyl)glycine	Naeg
25	D- $\alpha$ -methylhistidine	Dmhis	N-(3-aminopropyl)glycine	Norn
	D- $\alpha$ -methylisoleucine	Dmile	N-amino- $\alpha$ -methylbutyrate	Nmaabu
	D- $\alpha$ -methylleucine	Dmleu	$\alpha$ -naphthylalanine	Anap
	D- $\alpha$ -methyllysine	Dmlys	N-benzylglycine	Nphe
	D- $\alpha$ -methylmethionine	Dmmet	N-(2-carbamylethyl)glycine	Ngln
30	D- $\alpha$ -methylornithine	Dmorn	N-(carbamylmethyl)glycine	Nasn
	D- $\alpha$ -methylphenylalanine	Dmphe	N-(2-carboxyethyl)glycine	Nglu
	D- $\alpha$ -methylproline	Dmpro	N-(carboxymethyl)glycine	Nasp

	D- $\alpha$ -methylserine	Dmser	N-cyclobutylglycine	Ncbut
	D- $\alpha$ -methylthreonine	Dmthr	N-cycloheptylglycine	Nchep
	D- $\alpha$ -methyltryptophan	Dmtrp	N-cyclohexylglycine	Nchex
	D- $\alpha$ -methyltyrosine	Dmtyr	N-cyclodecylglycine	Ncdec
5	D- $\alpha$ -methylvaline	Dmval	N-cyclododecylglycine	Ncdod
	D-N-methylalanine	Dnmala	N-cyclooctylglycine	Ncoct
	D-N-methylarginine	Dnmarg	N-cyclopropylglycine	Ncpro
	D-N-methylasparagine	Dnmasn	N-cycloundecylglycine	Ncund
	D-N-methylaspartate	Dnmasp	N-(2,2-diphenylethyl)glycine	Nbhm
10	D-N-methylcysteine	Dnmcys	N-(3,3-diphenylpropyl)glycine	Nbhe
	D-N-methylglutamine	Dnmglu	N-(3-guanidinopropyl)glycine	Narg
	D-N-methylglutamate	Dnmglu	N-(1-hydroxyethyl)glycine	Nthr
	D-N-methylhistidine	Dnmhis	N-(hydroxyethyl)glycine	Nser
	D-N-methylisoleucine	Dnmile	N-(imidazolylethyl)glycine	Nhis
15	D-N-methylleucine	Dnmleu	N-(3-indolylyethyl)glycine	Nhtrp
	D-N-methyllysine	Dnmlys	N-methyl- $\gamma$ -aminobutyrate	Nmgabu
	N-methylcyclohexylalanine	Nmchexa	D-N-methylmethionine	Dnmmt
	D-N-methylornithine	Dnmorn	N-methylcyclopentylalanine	Nmcpn
	N-methylglycine	Nala	D-N-methylphenylalanine	Dnmphe
20	N-methylaminoisobutyrate	Nmaib	D-N-methylproline	Dnmpro
	N-(1-methylpropyl)glycine	Nile	D-N-methylserine	Dnmser
	N-(2-methylpropyl)glycine	Nleu	D-N-methylthreonine	Dnmthr
	D-N-methyltryptophan	Dnmtrp	N-(1-methylethyl)glycine	Nval
	D-N-methyltyrosine	Dnmtyr	N-methyl- $\alpha$ -naphthylalanine	Nmanap
25	D-N-methylvaline	Dnmval	N-methylpenicillamine	Nmpen
	$\gamma$ -aminobutyric acid	Gabu	N-( <i>p</i> -hydroxyphenyl)glycine	Nhtyr
	L- <i>t</i> -butylglycine	Tbug	N-(thiomethyl)glycine	Ncys
	L-ethylglycine	Etg	penicillamine	Pen
	L-homophenylalanine	Hphe	L- $\alpha$ -methylalanine	Mala
30	L- $\alpha$ -methylarginine	Marg	L- $\alpha$ -methylasparagine	Masn
	L- $\alpha$ -methylaspartate	Masp	L- $\alpha$ -methyl- <i>t</i> -butylglycine	Mtbug
	L- $\alpha$ -methylcysteine	Mcys	L-methylethylglycine	Metg

	L- $\alpha$ -methylglutamine	Mgln	L- $\alpha$ -methylglutamate	Mglu
	L- $\alpha$ -methylhistidine	Mhis	L- $\alpha$ -methylhomophenylalanine	Mhphe
	L- $\alpha$ -methylisoleucine	Mile	N-(2-methylthioethyl)glycine	Nmet
	L- $\alpha$ -methylleucine	Mleu	L- $\alpha$ -methyllysine	Mlys
5	L- $\alpha$ -methylmethionine	Mmet	L- $\alpha$ -methylnorleucine	Mnle
	L- $\alpha$ -methylnorvaline	Mnva	L- $\alpha$ -methylornithine	Morn
	L- $\alpha$ -methylphenylalanine	Mphe	L- $\alpha$ -methylproline	Mpro
	L- $\alpha$ -methylserine	Mser	L- $\alpha$ -methylthreonine	Mthr
	L- $\alpha$ -methyltryptophan	Mtrp	L- $\alpha$ -methyltyrosine	Mtyr
10	L- $\alpha$ -methylvaline	Mval	L-N-methylhomophenylalanine	Nmhpe
	N-(N-(2,2-diphenylethyl)	Nnbhm	N-(N-(3,3-diphenylpropyl)	Nnbhe
	carbamylmethyl)glycine		carbamylmethyl)glycine	
	1-carboxy-1-(2,2-diphenyl-	Nmbc		
	ethylamino)cyclopropane			

15

Crosslinkers can be used, for example, to stabilise 3D conformations, using homo-bifunctional crosslinkers such as the bifunctional imido esters having (CH<sub>2</sub>)<sub>n</sub> spacer groups with n=1 to n=6, glutaraldehyde, N-hydroxysuccinimide esters and hetero-bifunctional reagents which usually contain an amino-reactive moiety such as N-hydroxysuccinimide and another group specific-reactive moiety such as maleimido or dithio moiety (SH) or carbodiimide (COOH). In addition, peptides can be conformationally constrained by, for example, incorporation of C <sub>$\alpha$</sub>  and N <sub>$\alpha$</sub> -methylamino acids, introduction of double bonds between C <sub>$\alpha$</sub>  and C <sub>$\beta$</sub>  atoms of amino acids and the formation of cyclic peptides or analogues by introducing covalent bonds such as forming an amide bond between the N and C termini, between two side chains or between a side chain and the N or C terminus.

25

All these types of modifications may also be important to stabilise the subject polypeptide if used in a diagnostic or therapeutic test.

The present invention further contemplates functional equivalents of the subject polypeptides. Functional equivalents may not necessarily be derived from the polypeptides

themselves but may share certain conformational similarities. Alternatively, functional equivalents may be specifically designed to mimic certain physiochemical properties of the polypeptides. Functional equivalents may be chemically synthesised or may be detected following, for example, natural product screening.

- 5 Reference to the subject polypeptide from *Mycobacterium* species should be read as including reference to all forms of the polypeptide including, by way of example, isoforms or monomeric, dimeric or multimeric forms or peptide fragments of the polypeptide as well as derivatives, homologues, analogues and functional equivalents thereof.

- 10 The polypeptide of the present invention may contain a range of other molecules fused, linked, bound or otherwise associated to the polypeptide such as amino acids, lipids, carbohydrates or other peptides, polypeptides or proteins.

The polypeptides of the present invention may be a purified naturally occurring molecule, produced by chemical synthetic techniques or may be produced by recombinant DNA technology.

- 15 The present invention further contemplates a method of isolating a polypeptide from *Mycobacterium* species said method comprising culturing cells of said *Mycobacterium* species in a growth medium to increase the number of cells to a sufficient population, harvesting said cells and subjecting said cells to protein extraction techniques to extract protein from said cells, fractionating the extracted protein and subjecting said protein to  
20 binding analysis with antibodies to said *Mycobacterium* species or antigenic portions thereof and isolating the polypeptides to which antibodies interact.

Preferably, the *Mycobacterium* species in *M. tuberculosis*.

Preferably, the growth medium is Lowenstein-Jensen medium.

- 25 Preferably, fractionation of total polypeptides from *M. tuberculosis* is conducted by SDS-PAGE.

Preferably, the binding analysis in a Western blot analysis.

The isolated polypeptide bands are then generally subjected to N-terminal, C-terminal or internal amino acid sequencing. Nucleotide probes are then produced and cDNA or genomic libraries screened for genetic sequences encoding the isolated polypeptides.

- 5 In a particularly preferred embodiment, the polypeptide of the present invention comprises an N-terminal amino acid sequence substantially as set forth in one of SEQ ID NOs: 1 to 10 or an amino acid sequence having at least about 70% similarity thereto.

10 The term "similarity" as used herein includes exact identity between compared sequences at the nucleotide or amino acid level. Where there is non-identity at the nucleotide level, "similarity" includes differences between sequences which result in different amino acids that are nevertheless related to each other at the structural, functional, biochemical and/or conformational levels. Where there is non-identity at the amino acid level, "similarity" includes amino acids that are nevertheless related to each other at the structural, functional, biochemical and/or conformational levels. In a particularly preferred embodiment,  
15 nucleotide and sequence comparisons are made at the level of identity rather than similarity.

Any number of programs are available to compare nucleotide and amino acid sequences. Preferred programs have regard to an appropriate alignment. One such program is Gap which considers all possible alignment and gap positions and creates an alignment with the largest number of matched bases and the fewest gaps. Gap uses the alignment method of  
20 Needleman and Wunsch (9). Gap reads a scoring matrix that contains values for every possible GCG symbol match. GAP is available on ANGIS (Australian National Genomic Information Service) at website <http://mell1.angis.org.au..>

Yet another aspect of the present invention is directed to genetic sequences encoding the polypeptide herein described.

- 25 Accordingly, another aspect of the present invention provides an isolated nucleic acid molecule comprising a sequence of nucleotides encoding or complementary to a sequence encoding a polypeptide obtainable from a species of *Mycobacterium* and which polypeptide is immunointeractive with sera from a human, animal or avian species exposed to said species of



*Mycobacterium* or its relative or antigenic parts thereof but which polypeptide is substantially not immunointeractive with sera from a human, animal or avian species not prior exposed to said species of *Mycobacterium* or its relative or its antigenic parts.

5 The preferred *Mycobacterium* species in *M. tuberculosis* although the present invention extends to any species of *Mycobacterium* or its relatives.

Preferably, the nucleotide sequence encodes an amino acid sequence substantially as set forth in one of SEQ ID NOs: 1 to 10 or an amino acid sequence having at least about 70% similarity thereto.

10 The nucleic acid molecule of this aspect of the present invention may be cDNA, genomic DNA or mRNA or cDNA/genomic DNA or DNA/RNA hybrids. The nucleotide sequence may encode the amino acid sequence of the naturally occurring polypeptide or it may encode a mutant, fragment, part or other derivative of the polypeptide. Accordingly, the nucleotide sequence may contain one or more nucleotide substitutions, deletions and/or additions to the naturally occurring sequence.

15 The nucleotide acid molecule of the present invention may be linear or covalently closed single or double stranded molecules, alone or as part of a genetic construct such as an expression vector and/or purification vector.

20 Still another aspect of the present invention is directed to antibodies to the subject polypeptides or their derivatives, homologues, analogues, mimetics and functional equivalents thereof. Such antibodies may be monoclonal or polyclonal. Where the derivatives are peptides, these may first need to be associated with a carrier molecule in order to induce antibody formation.

25 The antibodies of the present invention are particularly useful as therapeutic or diagnostic agents. For example, specific antibodies can be used to assist in screening for polypeptides in immunoassays or used as antagonists to inhibit polypeptide activity under certain circumstances. Techniques for such immunoassays are well known in the art and include, for example, sandwich assays and ELISA. Knowledge of polypeptide levels may be

important for monitoring certain therapeutic protocols.

As stated above, the antibodies may be monoclonal or polyclonal antibodies. Alternatively, fragments of antibodies may be used such as Fab fragments. Furthermore, the present invention extends to recombinant and synthetic antibodies and to antibody hybrids. A "synthetic antibody" is considered herein to include fragments and hybrids of antibodies.

As stated above, specific antibodies can be used to screen for the subject polypeptides. The latter would be important, for example, as a means for screening for levels of polypeptides in a cell extract or other biological fluid or purifying polypeptides made by recombinant means from culture supernatant fluid. The antibodies may also be used to screen for the presence of particular *Mycobacterium* polypeptides. The presence of *M. tuberculosis* polypeptides, for example, is indicative of tuberculosis.

It is within the scope of this invention to include any second antibodies (monoclonal, polyclonal or fragments of antibodies or synthetic antibodies) directed to the first mentioned antibodies discussed above. Both the first and second antibodies may be used in detection assays or a first antibody may be used with a commercially available anti-immunoglobulin antibody. An antibody as contemplated herein includes any antibody specific to any region of polypeptide.

Both polyclonal and monoclonal antibodies are obtainable by immunization with the *Mycobacterium* polypeptides either type is utilizable for immunoassays. The methods of obtaining both types of sera are well known in the art. Polyclonal sera are less preferred but are relatively easily prepared by injection of a suitable laboratory animal with an effective amount of polypeptide, or antigenic parts thereof, collecting serum from the animal and isolating specific sera by any of the known immunoabsorbent techniques. Although antibodies produced by this method are utilizable in virtually any type of immunoassay, they are generally less favoured because of the potential heterogeneity of the product.

The use of monoclonal antibodies in an immunoassay is particularly preferred because of the ability to produce them in large quantities and the homogeneity of the product. The

preparation of hybridoma cell lines for monoclonal antibody production derived by fusing an immortal cell line and lymphocytes sensitized against the immunogenic preparation can be done by techniques which are well known to those who are skilled in the art.

Another aspect of the present invention contemplates a method for detecting a subject polypeptide in a biological sample from a subject or culture supernatant flow or other source said method comprising contacting said biological sample with an antibody specific for said polypeptide or its derivative, homologue, analogue, mimetic or chemical equivalent thereof for a time and under conditions sufficient for an antibody-polypeptide complex to form, and then detecting said complex.

- 10 The presence of the polypeptide may be accomplished in a number of ways such as by Western blotting and ELISA procedures. A wide range of immunoassay techniques are available as can be seen by reference to US Patent Nos. 4,016,043, 4, 424,279 and 4,018,653. These include both single-site and two-site or "sandwich" assays of the non-competitive types, as well as in the traditional competitive binding assays. These assays also  
15 include direct binding of a labelled antibody to a target.

- A number of variations of the sandwich assay technique exist, and all are intended to be encompassed by the present invention. Briefly, in one form of forward assay, an unlabelled *Mycobacterium* polypeptide is immobilized on a solid substrate and a sample of animal (e.g. human) sera to be tested brought into contact with the bound molecule. After a suitable  
20 period of incubation, for a period of time sufficient to allow formation of a polypeptide-antibody complex, a second antibody specific to animal (e.g. human) immunoglobulin, labelled with a reporter molecule capable of producing a detectable signal is then added and incubated, allowing time sufficient for the formation of another complex of polypeptide-antibody labelled antibody. Any unreacted material is washed away, and the presence of  
25 polypeptide specific antibody determined by observation of a signal produced by the reporter molecule or the anti-animal (e.g. human) immunoglobulin. The results may either be qualitative, by simple observation of the visible signal, or may be quantitated by comparing with a control sample containing known amounts of hapten. Variations on the forward assay include a simultaneous assay, in which both sample and labelled antibody are added

simultaneously to the bound antibody. These techniques are well known to those skilled in the art, including any minor variations as will be readily apparent. The method of this aspect of the present invention may readily be adapted for screening for *Mycobacterium* polypeptide by, for example, immobilizing an antibody specific for the polypeptide.

- 5 Immobilization of polypeptide or antibody either covalent or passive binding to a solid surface. The solid surface is typically glass or a polymer, the most commonly used polymers being cellulose, nitrocellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride or polypropylene. The solid supports may be in the form of tubes, beads, discs of microplates, cover slips, slides or any other surface suitable for conducting an immunoassay.
- 10 The binding processes are well-known in the art and generally consist of cross-linking covalently binding or physically adsorbing the polypeptide or antibody to the solid support. An aliquot of the sample to be tested is then added to the solid phase complex and incubated for a period of time sufficient (e.g. 2-40 minutes or overnight if more convenient) and under suitable conditions (e.g. from room temperature to about 37°C) to allow binding of the
- 15 polypeptide or antibody to its immobilized ligand. Following the incubation period, the solid phase is washed and dried and incubated with an antibody specific for a portion of the polypeptide or antibody. This antibody is linked to a reporter molecule which is used to indicate the binding of the antibody to its ligand.

- An alternative method involves immobilizing the target molecules in the biological sample
- 20 and then exposing the immobilized target to specific antibody which may or may not be labelled with a reporter molecule. Depending on the amount of target and the strength of the reporter molecule signal, a bound target may be detectable by direct labelling with the antibody. Alternatively, a second labelled antibody, specific to the first antibody is exposed to the target-first antibody complex to form a target-first antibody-second antibody tertiary
- 25 complex. The complex is detected by the signal emitted by the reporter molecule.

By "reporter molecule" as used in the present specification, is meant a molecule which, by its chemical nature, provides an analytically identifiable signal which allows the detection of antigen-bound antibody. Detection may be either qualitative or quantitative. The most commonly used reporter molecules in this type of assay are either enzymes, fluorophores or

radionuclide containing molecules (i.e. radioisotopes), chemiluminescent molecules colloidal material and precious metals such as gold.

In the case of an enzyme immunoassay, an enzyme is conjugated to the second antibody, generally by means of glutaraldehyde or periodate. As will be readily recognized, however, a wide variety of different conjugation techniques exist, which are readily available to the skilled artisan. Commonly used enzymes include horseradish peroxidase, luciferase, glucose oxidase,  $\beta$ -galactosidase and alkaline phosphatase, amongst others. The substrates to be used with the specific enzymes are generally chosen for the production, upon hydrolysis by the corresponding enzyme, of a detectable colour change. Examples of suitable enzymes include alkaline phosphatase and peroxidase. It is also possible to employ fluorogenic substrates which yield a fluorescent product rather than the chromogenic substrates noted above. In all cases, the enzyme-labelled antibody is added to the antibody-polypeptide complex, allowed to bind, and then the excess reagent is washed away. A solution containing the appropriate substrate is then added to the complex of antibody-polypeptide-antibody. The substrate will react with the enzyme linked to the antibody, giving a qualitative visual signal, which may be further quantitated, usually spectrophotometrically, to give an indication of the amount of polypeptide which is present in the sample. The reporter molecule also extends to use of cell agglutination or inhibition of agglutination such as red blood cells on latex beads and the like.

Alternately, fluorescent compounds, such as fluorescein and rhodamine, may be chemically coupled to antibodies without altering their binding capacity. When activated by illumination with light of a particular wavelength, the fluorochrome-labelled antibody adsorbs the light energy, inducing a state to excitability in the molecule, followed by emission of the light at a characteristic colour visually detectable with a light microscope. As in the EIA, the fluorescent labelled antibody is allowed to bind to the antibody-polypeptide complex. After washing off the unbound reagent, the remaining tertiary complex is then exposed to the light of the appropriate wavelength the fluorescence observed indicates the presence of the polypeptide of interest. Other reporter molecules, such as radioisotope, chemiluminescent or bioluminescent molecules, may also be employed.

The polypeptides of the present invention and antibodies thereto are useful for detecting *Mycobacterium* infection and/or disease or other conditions associated with *Mycobacterium*. The presence of *Mycobacterium* in environmental samples may also be accomplished. In a particularly preferred embodiment, polypeptides derived from *M. tuberculosis* are detected. In this case, the polypeptides are particularly useful in detecting tuberculosis.

Accordingly, another aspect of the present invention contemplates a method for detecting the presence of *M. tuberculosis* such as in a patient suffering from tuberculosis said method comprising contacting a biological sample from a patient or subject with an antibody specific for a polypeptide from said *M. tuberculosis* and detecting a complex between said polypeptide and said antibody.

In an alternative embodiment there is provided a method for detecting the presence of *M. tuberculosis* such as in a patient suffering from tuberculosis said method comprising contacting a sera sample from a patient or subject with a polypeptide from *M. tuberculosis* and detecting a complex between said polypeptide and an antibody in said sera.

The polypeptide-antibody complex may be detected by any convenient means. One particularly useful method is to detect the complex using an anti-immunoglobulin labelled with a reporter molecule such as but not limited to colloidal gold, an enzyme, a radioactive isotope or a fluorescent compound.

In a particularly preferred embodiment, one or more polypeptides from *M. tuberculosis* are immobilized onto a solid support. Sera from a patient suspected of having exposure to *M. tuberculosis* are then brought into contact with immobilized polypeptides(s). After a time sufficient from an immobilized polypeptide-antibody complex to form, unbound material is washed away and an anti-human immunoglobulin labelled with a reporter molecule is brought into contact to bind to human antibodies in the sera of a patient which have bound to the immobilized *M. tuberculosis* polypeptide. The presence of an identifiable signal from the reporter molecule indicates the presence of the polypeptide and of *M. tuberculosis*. This is a particularly convenient means of identifying tuberculosis or a likelihood of tuberculosis or its possible development.

Reference herein to "tuberculosis" includes reference to pulmonary and extra-pulmonary

tuberculosis.

There are many different ways of conducting this assay. For example, an application matrix comprising absorbable material such as filter paper and the like may comprise an application region, a *M. tuberculosis* polypeptide region and detection region. In the arrangement, sera from a patient or subject to be tested are applied to the application region and allowed to passage (i.e. "wick") along the application matrix through a region comprising impregnated *M. tuberculosis* polypeptide or its derivatives, homologues, analogues or antigenic equivalents. If antibodies are present in the sera specific for the polypeptide, a complex will form. This complex may be detected directly by the application of an anti-human immunoglobulin antibody labelled with a reporter molecule or the complex may be allowed to migrate into a third region impregnated with anti-human immunoglobulin antibody labelled with a reporter molecule. The identifiable signal produced by the reporter molecule can then be detected in that third region or in a fourth region where the sera-polypeptide-labelled antibody is permitted to concentrate.

In a particularly preferred embodiment, there is provided an assay device for *M. tuberculosis* comprising a solid support having immobilized thereon one or more polypeptides obtainable from *M. tuberculosis* or derivatives, homologues, analogues or antigenic equivalents thereof and a portion of said solid support adapted for receiving a sample from a human subject to be tested wherein said sample would contain an antibody specific for said *M. tuberculosis* polypeptide if said subject has been exposed to *M. tuberculosis* wherein upon contact between the antibody from the subject and the immobilized polypeptide, a complex forms and said complex is detected by an anti-human immunoglobulin labelled with a reporter molecule.

Yet another preferred assay technique comprises applying sera from a subject to be tested to an application matrix and allowing the sera to passage (i.e. "wick") along the matrix and into an area impregnated with recombinant polypeptides from *Mycobacterium* species and in particular *M. tuberculosis*. A complex forms between antibodies in the sera and the polypeptides and these complexes as well as free antibodies and free polypeptides continue to migrate to a region comprising anti-human antibodies labelled a reporter molecule such as, for example, gold. The passing molecules then enter a region with reduced pore size such as an area containing nitrocellulose. The molecules which are not part of a complex pass through this region whereas complexes of antibodies and polypeptides tend to concentrate as a band in

front of the region with reduced pore size (e.g. nitrocellulose region). If the label is gold the line of complexes is pink or like colour or black. If silver stained or blue when the label is coloured latex particles.

5 Regardless of the assay procedure, and whether or not "wicking" is involved, one particularly useful procedure for detecting antibody-polypeptide interactivity is through electronic means such as described in US Patent No. 5,580,794.

10 All such electronic detection means are contemplated for use in accordance with the present invention. For example, interaction between certain molecules may lead to the production of an electrical signal which in turn, *via* a signal processor, correlates with the amount of interaction of amount of certain components of an interaction.

The present invention extends to the detection of a single type or species of *Mycobacterium* polypeptide as well as to the detection of a combination of *Mycobacterium* polypeptides. The detection of combinations of antigens may be accomplished, for example, by using a multiple array of antibodies.

15 The identification and isolation of the *Mycobacterium* species polypeptide of the present invention further permits the development of therapeutic protocols for generating, for example, an immune response directed to *Mycobacterium* species. Preferably, the *Mycobacterium* species is *M. tuberculosis*.

20 Accordingly, the present invention contemplates a composition comprising one or more polypeptides for *Mycobacterium* species or a derivative, homologue, analogue, mimetic or chemical equivalent thereof and one or more pharmaceutically acceptable carriers and/or diluents. These components are referred to as the "active ingredients". Preferably, the polypeptides are from *M. tuberculosis* and the composition is capable of inducing an immune response against *M. tuberculosis*.

25 The compositions suitable for injectable use include sterile aqueous solutions (where water soluble) and sterile powders for the extemporaneous preparation of sterile injectable solutions. It must be stable under the conditions of manufacture and storage and must be



preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils. The preventions of the action of  
5 microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimersal and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate  
10 and gelatin.

Sterile injectable solutions are prepared by incorporating the polypeptide or other active compounds in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilization. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of  
15 preparation are vacuum drying and the freeze-drying technique which yield a powder of the active ingredient plus any additional desired ingredient from previously sterile-filtered solution thereof.

Pharmaceutically acceptable carriers and/or diluents include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents  
20 and the like.

The principal active ingredient, i.e. the polypeptide, will be present in the composition in an amount effective to induce an immune response. The composition may permit, for example, 0.01  $\mu\text{g}$  to about 2000 mg/kg body weight.

The pharmaceutical composition may also comprise genetic molecules such as a vector  
25 capable of transfecting target cells where the vector carries a nucleic acid molecule capable of modulating expression of genes encoding a polypeptide from *Mycobacterium* species. The vector may, for example, be a viral vector.

The present invention further contemplates the use of a polypeptide from *Mycobacterium* species such as *M. tuberculosis* or a derivative, homologue, analogue, mimetic or chemical equivalent thereof in the manufacture of a medicament for the treatment of *Mycobacterium* infection such as tuberculosis.

- 5 The present invention is further described by the following non-limiting Examples.

### EXAMPLE 1

#### Extraction of *M. tuberculosis* total protein

- Mycobacterium tuberculosis* cells (ATCC 27294) were cultured in BBL MycoFlask containing Lowenstein-Jensen medium at 37°C with 10% v/v CO<sub>2</sub>. After 2 weeks, the  
10 confluent cells were harvested, washed and resuspended in an equal volume of MilliQ H<sub>2</sub>O. The cell suspension was heated to 90°C for 2h after which it was frozen at -20°C overnight. Thawed cells were sonicated for 2-3min and pelleted at 14,000rpm for 10min. Extraction of total protein was performed in 8M urea (equal ratio of weight of cells to volume of 8M urea). The cell suspension was vortexed at room temperature for 20 min heated at 90°C for  
15 2min. Insoluble cellular debris was pelleted at 14,000rpm for 10min and the supernatant containing the extracted total protein was kept at -20°C until further use.

### EXAMPLE 2

#### SDS-PAGE analysis and immunological analysis

- The total protein extract from *M. tuberculosis* was fractionated on a 7.5% w/w SDS-PAGE  
20 (10) and transferred onto a nitrocellulose membrane by the conventional western blot method (11). Strips containing the Western blotted *M. tuberculosis* total proteins were immunoscreened with pooled sera from 9 patients having active tuberculosis (TB) and pooled sera from 7 normal non-infected individuals, respectively. Detection was carried out using the goat anti-human Ig conjugated with alkaline phosphatase (Harlan Sera lab, UK).

### EXAMPLE 3

#### N-terminal sequencing of *M. tuberculosis* bands

Several individual protein bands (Mwt ranging from 10 to 160 kDa), which reacted positively in the immunoscreening, were excised from a preparative 7.5% w/v SDS-polyacrylamide gel, and concentrated on a long stacking gel (7cm of 4% w/v stacking gel, 5cm of 10% w/v resolving gel). After concentration, the protein bands were blotted onto a PVDF membrane and subsequently stained with Coomassie Brilliant Blue R-250. The stained protein bands were then excised from the membrane and used for N-terminal microsequencing. In addition, some of the protein bands were also blotted onto nitrocellulose membrane to repeat immunoscreening using the same pooled sera samples as previously described.

### EXAMPLE 4

#### Screening the *Eco*R1 lambda ZAP phage expression library of *M. tuberculosis* genomic DNA

15 An expression library of *Eco*R1 restricted genomic DNA of *M. tuberculosis* was constructed in lambda ZAP Phage expression vector (according to the protocol by Stratagene (12)). The resultant library have 98% of recombinants ( $2 \times 10^6$  pfu/ $\mu$ g arms) and insert sizes ranging from 0.7-2kb, observed in excised recombinant plasmids restricted with *Eco*R1 restriction enzyme. A lawn of XL1-MRF' cells infected with about  $2 \times 10^4$  pfu of the phage stock was prepared on a 150 mm plate, and incubated inverted, for 6-7 hr at 42°C. The lawn was then overlaid with a Hybond-C filters, presoaked in 1mM IPTG for induction of protein expression and were incubated at 37°C for 4hr, causing the transfer of expressed TB recombinant proteins from the plaques onto the membrane. The plate and filter were indexed for matching of corresponding plate and filter positions. About 20 plates were prepared for the library and as a negative control, a lawn of host cells infected with  $2 \times 10^4$  pfu of the non-recombinant lambda ZAP phage was used instead.

Filters were washed twice in TBST buffer (10mM Tris, pH7.5, 300mM NaCl, 0.005% v/v

Tween 20), blocked in 5% w/v skim milk in TBST, washed again in TBST and used to screen against 4 pooled active TB sera and pooled normal sera, respectively. The pre-absorption regime for the pooled sera was as follows: negative control filters containing proteins from induced lambda ZAP phage vector in the bacteria host was used. Pooled sera  
5 (diluted 1:100 in 1% w/v skim milk/TBST) was incubated (15ml/filter) for 2hr at RT after which sera was diluted to 1:200 in 1% w/v skim milk/TBST and transferred to a fresh control filter for overnight preabsorption. Screening was as follow: filters containing the expressed recombinant proteins from the phage library were incubated with pre-absorbed human sera for 2 hr, rocking at RT and washed three times in TBST. Secondary antibody of  
10 anti-human Ig - alkaline phosphatase conjugated (diluted 1:1000 in 1% w/v skim milk/TBST) was added and allowed to incubate for 1hr. After a final wash, the detection was by colormetric, using NBT/BCIP substrate. An immunoreactive recombinant clone, C17, was isolated and confirmed in the tertiary screening.

Secondary and tertiary plating: positive plaques were cored out and phage eluted in SM  
15 bufffer (13) containing 2% v/v chloroform and replated at about 100-200 pfu on a 82mm plates. The screening steps using pooled sera were repeated to confirm the positive clones. In the tertiary screening 6 positive phage recombinants were obtained and these were subsequently subjected to plasmid excision (12). Restriction enzyme *EcoR*I digestion indicated that all the clones have a 2kb insert which was later confirmed to be identical by  
20 DNA sequencing. The clones were designated as C17 and have a 1.16 kb open reading frame (in frame with the vector ATG initiation codon) coding for a  $38 \pm 3$  kDa protein.

## EXAMPLE 5

### Cloning and expression of genes for the *M. tuberculosis* antigens

Primers were designed from the N-terminal sequences. Polymerase chain reaction (PCR)  
25 was performed using the Advantage®-GC Genomic PCR kit (Clontech), *M. tuberculosis* genomic DNA (extracted as previously described (14)) and synthetic oligonucleotides. The PCR products were cloned into the pGEMT vector (Promega) before subcloning into the pQE30 expression vector (15) (Fig. 1). Expression was carried out in *M*<sub>15</sub> *E.coli* cells, induced with 1mM IPTG. The *M*<sub>15</sub> cells at 3hr after induction were harvested, and cell

pellet lysed in 8M urea buffer at pH6.5. The expressed recombinant protein contained a 6x histidine tag at the N-terminus which facilitated the purification with the Ni-NTA affinity column. Column washes were carried out in 8M urea buffer at pH 6.5 and pH 5.9 while subsequently elution of recombinant protein was carried out at pH4.5.

5 Table 2 provides the gene sizes for each TB antigen and the theoretical mass.

**TABLE 2**  
**GENE SIZE AND PHYSICAL CHARACTERISTICS OF TB ANTIGENS**

Antigen	Size of gene (kb)	Theoretical*	
		Molecular mass	pI value
B.4	1.617	55.8	5.12
B.6	1.560	55.0	5.03
B.10	0.903	32.9	4.95
MMP	0.432	16.1	5.00
C17	1.161	37.5	9.43

10 \* obtained using the software "Compute pI/Mwt" from ExPASy homepage, Swiss Institute of Bioinformatics, Geneva

The gene size of each TB antigen and the theoretical molecular mass and pI values as calculated from the respective deduced amino acid sequence. The resultant recombinant proteins will be approximately 1.4 to 1.5-kDa larger than the theoretical molecular mass  
15 shown, due to the 6x Histidine tag at the N-terminal.

## EXAMPLE 6

### SDS-PAGE and Western blot of *M. tuberculosis* recombinant antigens

A total of 27 $\mu$ g of a partially purified recombinant antigen was subjected to a SDS-PAGE electrophoresis at 180V for 1hr. The recombinant antigen was transferred from the polyacrylmide gel onto a Hybond-nitrocellulose membrane (Amersham) by Western blot (11), using the BioRad TransBlotter (according to manufacturer's protocol). After transfer, the membrane was blocked in 5% w/v milk/TBST, air dried and stored at 4°C until further use.

## EXAMPLE 7

### Screening of the recombinant *M. tuberculosis* antigens against active (pulmonary and extra-pulmonary), inactive and normal sera panels

Each membrane was cut into strips (a total of 23 strips can be obtained from each blot) and each strip was used for screening with a serum sample. One strip was used as an internal positive of known serum sample which reacted with the recombinant protein antigen and another was used to probe with the commercially available anti-RGSHis probe (QIAGEN). Sera samples were diluted to 1:100 in 1% w/v milk/TBST. Screening was carried out in tubes individually (2 strips/tube) and 3ml of diluted serum/tubes for 1hr with rocking at room temperature. The strips were then washed 3 times in TBST and were incubated with Goat anti-human Ig alkaline phosphatase conjugated (Harlan Sera lab) for 1hr with rocking at room temperature. The strips were washed 3 times in TBST and allowed to develop in 1ml of NBT/BCIP substrate (BioRad) for 4 mins.

Reactivity of recombinant protein to patient sera was interpreted based on the intensity of band observed, ie. negative, + and 2+; the later two were taken as a positive. Faintly stained bands were scored negative.

Using the above screening procedure, the five recombinant antigens were screened against a total of 85 human sera; 43 were from bacteriologically confirmed tuberculosis patients [23 pulmonary, 20 extra-pulmonary]; 22 inactive samples (with skin PPD tve but smear and

bacteria culture negative); and 20 sera samples of uninfected individuals previously vaccinated with BCG. All sera were stored at -70°C before use.

## EXAMPLE 8

### Identification of *M. tuberculosis* polypeptides

- 5 Immunological analysis of Western blotted *M. tuberculosis* total proteins gave 9 protein bands which reacted with the 9 pooled active sera but not with the 7 pooled normal sera. The respective bands were concentrated on a long stacking gel and excised. Excised protein bands were reactive with the pooled active sera but not with pooled normal sera, thus confirming the authenticity of these excised proteins as initially observed in the primary
- 10 screening (Fig. 2). These proteins were identified by homology searches against protein sequence databases and the result gave a high percentage of homology to *Mycobacterium* proteins (Fig. 3). Primers for PCR were constructed to isolate gene that codes for proteins which gave the high homology (Fig. 1). B.4, B.6, B.10, C17 and MMP were among the genes in addition to B.5 (16), B.9 and 38 kDa isolated from *M. tuberculosis* genomic DNA.
- 15 The QIAGEN expression system was selected by the inventors for cloning and expression of the corresponding genes. This system utilizes the pQE30 vector whereby the expressed protein can be purified through a simple one step affinity chromatography and insoluble recombinant proteins can be purified under denaturation conditions (Fig. 1). Expression of recombinant proteins can be immuno-detected by the commercially available anti-RGSHis.
- 20 In addition, the 6xHis tag is non-immunogenic and thus the purified recombinant protein can be used directly in a Western blot format for screening against the sera.

From the expression studies, B.4, B.5, B.9, MMP and 38 kDa gave high level of expression whereas B.6, B.10 and C17 expression level was low. All of these recombinant proteins were detected by anti-RGSHis. In addition, most of the recombinant proteins were insoluble

25 except for B.5 and C 17 which was soluble. As such the format of choice for our initial screening was on a Western format.

Results of Western screening and the intensity of band observed on the strip is as shown in

Figure 4. Percentage of reactivity were calculated based on the number of sera which gave positive (+ or 2+ observed on the strip) divided by the number of sera sample screened.

Figure 5 shows the percentage of reactivity of recombinant TB antigens against different sera panels. A known 38kDa antigen (7, 8) of *M. tuberculosis* was included in the screening.

5 The gene (GeneBank Accession # M30046) for this antigen was cloned, expressed in pQE30 and partially purified. Also shown are the percentages of reactivity of sera samples detected by a commercially available rapid TB diagnostic kit from ICT (Amrad).

Analysis of the screening result is as shown in Figure 5 and Figure 6. B.6, B.9, B.10, C17, MMP and 38 kDa antigens showed no reactivity to the sera from uninfected individuals  
10 whereas B.4 and B.5 reacted to 5% and 25% of this panel respectively. B.4 and B.5 may have some epitopes which are recognised by antibodies present in uninfected animals. All of these recombinant antigens showed some reactivity to sera from the active TB panel, both pulmonary and extra-pulmonary. B.6 (52.2%) and B.10 (26.1%) seems to be specifically reactive to active pulmonary samples whereas MMP (25%) is specific to extra-pulmonary  
15 samples. All of the recombinant samples, except for B.5 and have low reactivity (<25%) to the inactive sera panel. This is important because a good seriological diagnostic marker would be one that allow differentiation of normal and individuals having previous infection of TB (inactive) from individuals with active tuberculosis.

Overall, the percentage of reactivity to sera panels increased when more recombinant  
20 antigens were included in the combination. This is in accordance with the observation that sensitivity increases with the number of antigens used for screening. Combinations including all recombinant antigens (B.4 + B.5 + B.6 + B.9 + B.10 + C17 + MMP+38kDa) gave a sensitivity of more than 90%. However the reactivity to inactive sera samples was also high (36%). Results indicate that the best combination of antigens to use  
25 is one that include B.6, B.10, B.4, MMP and C17 which gives a sensitivity of 60-70% to active sera, both pulmonary and extra-pulmonary. Specificity for this combination is 95% but reaches to 100% if excluding B.4 which as indicated earlier exhibited 5% reactivity to sera from uninfected individuals.

Comparison of reactivity against the different sera panel for the combination of all the



recombinant TB antigens compared to the ICT TB diagnostic kit. The graph shows that the percentage of reactivity for the active sera panel (pulmonary and extra-pulmonary) is higher than that observed for the kit.

Combination of antigens (B.6 + B.10 + MMP + 38 kDa) gave a sensitivity (60-70%) higher than that observed for the ICT kit (50%); the reactivity to inactive panel is comparable to that for ICT (Figure 9). As this is not an optimized assay, the sensitivity and specificity can be increased further using a panel of combined recombinant antigens which includes B.4, B.6, B.10, MMP and C17.

### EXAMPLE 9

#### **Determination of nucleotide and amino acid sequences of *Mycobacterium* antigens**

Nucleotide sequences and corresponding amino acid sequences were determined for antigens B.4, B.6, B.10, C17 and MMP and are shown in <400>1, <400>3, <400>5, <400>7, <400>9 respectively.

Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. It is to be understood that the invention includes all such variations and modifications. The invention also includes all of the steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations of any two or more of said steps or features.

## BIBLIOGRAPHY

1. Davis B. D. *et al*, *Microbiology*, 2nd Edition, Harper International Edition. Harper & Row Publishers. pp 844-869, 1973.
2. Murray C.J.L, *et al*, *Bull Int Union Tuberc Lung Dis* 65: 6-24, 1990.
- 5 3. Shinnick TM *et al*, *Clin Infect Dis* 21: 291-299, 1995.
4. Beige J, *et al*, *J Clin Microbiol*, 33: 90-95, 1995.
5. Banica D., *et al*, *Pneumoftiziologia*, 43: 173-177, 1994.
6. Bothamley GH *Eur Respir J Suppl* 20: 676S-688S, 1995.
7. Andersen *et al*, *Infect. Immun*, 57: 2481-2488, 1989.
- 10 8. Wilkinson *et al.*, *J. Clin Micro*, 35: 553-557, 1997.
9. Needleman and Wunsch *J. Mol. Biol.* 48: 443-453, 1970.
10. Laemmli, *et al*, *Nature (London)*, 227: 680-685, 1970.
11. Towbin H, *et al*, *Proc. Natl. Acad. Sci. USA* 76: 4350-4354.
12. ZAP Express™ cDNA Synthesis Kit, Manual, Stratagene Cloning systems.
- 15 13. Maniatis *et al*, "Molecular Cloning: a laboratory manual. Cold Spring harbor Laboratory, Cold Spring Harbor, N.Y. (1982).
14. Parra C.A, *et al.*, *Infect. & Immun*; 59: 3411-3417, 1991.
15. QIAGEN GmbH and QIAGEN Inc. The QIAexpressionist- The high level expression & protein purification system.
- 20 16. Shinnick *et al.*, *J. Bacteriol* 169: 1080-1088, 1987.
17. Marmur and Doty *J. Mol. Biol.* 5: 109, 1962.
18. Bonner and Laskey *Eur. J. Biochem.* 46: 83, 1974.
19. Needleman and Wunsch *J. Mol. Biol.* 48: 443-453, 1970.

SEQUENCE LISTING

<110> National University of Singapore

<120> Bacterial-derived molecules and therapeutic and diagnostic uses therefor

5 <130> Mycobacterium tuberculosis antigens

<140>

<141>

<160> 14

<170> PatentIn Ver. 2.1

10 <210> 1

<211> 1617

<212> DNA

<213> Mycobacterium tuberculosis

<220>

15 <221> CDS

<222> (1)..(1617)

<220>

<221> mat\_peptide

<222> (1)..(1617)

20 <400> 1

agc	aag	ctg	atc	gaa	tac	gac	gaa	acc	gcg	cgt	cgc	gcc	atg	gag	gtc	48
Ser	Lys	Leu	Ile	Glu	Tyr	Asp	Glu	Thr	Ala	Arg	Arg	Ala	Met	Glu	Val	
1				5					10					15		

ggc	atg	gac	aag	ctg	gcc	gac	acc	gtg	cgg	gtg	acg	ctg	ggg	ccg	cgc	96
Gly	Met	Asp	Lys	Leu	Ala	Asp	Thr	Val	Arg	Val	Thr	Leu	Gly	Pro	Arg	
			20					25					30			

ggc	cgg	cat	gtg	gtg	ctg	gcc	aag	gcg	ttt	ggc	gga	ccc	acg	gtt	acc	144
Gly	Arg	His	Val	Val	Leu	Ala	Lys	Ala	Phe	Gly	Gly	Pro	Thr	Val	Thr	
		35					40					45				

aac	gac	ggc	gtc	acg	gtg	gca	cgt	gag	atc	gag	ctg	gaa	gat	ccg	ttt	192
Asn	Asp	Gly	Val	Thr	Val	Ala	Arg	Glu	Ile	Glu	Leu	Glu	Asp	Pro	Phe	
	50					55					60					

gaa	gac	ttg	ggc	gcc	cag	ctg	gtg	aag	tgc	gtg	gcc	acc	aag	acc	aac	240
Glu	Asp	Leu	Gly	Ala	Gln	Leu	Val	Lys	Ser	Val	Ala	Thr	Lys	Thr	Asn	
	65				70				75					80		

gat	gtt	gcc	ggt	gac	ggc	acc	acc	acc	gca	acc	atc	ttg	gcg	cag	gca	288
Asp	Val	Ala	Gly	Asp	Gly	Thr	Thr	Thr	Ala	Thr	Ile	Leu	Ala	Gln	Ala	
			85					90						95		

ctg	atc	aag	ggc	ggc	ctg	agg	cta	gtg	gcc	gcc	ggc	gtc	aac	ccg	gtc	336
Leu	Ile	Lys	Gly	Gly	Leu	Arg	Leu	Val	Ala	Ala	Gly	Val	Asn	Pro	Val	
			100					105					110			

gcg	ctc	ggc	gtg	gga	atc	ggc	aag	gcc	gcc	gac	gcg	gta	ttc	gag	gcg	384
Ala	Leu	Gly	Val	Gly	Ile	Gly	Lys	Ala	Ala	Asp	Ala	Val	Phe	Glu	Ala	
		115					120					125				

	ctg ctg gca tcg gcc acg ccg gtg tcc ggc aag acc ggc atc gcg cag	432
	Leu Leu Ala Ser Ala Thr Pro Val Ser Gly Lys Thr Gly Ile Ala Gln	
	130 135 140	
5	gtg gcg acg gtg tcc tcg cgc gac gag cag atc ggt gac ctg gtt ggc	480
	Val Ala Thr Val Ser Ser Arg Asp Glu Gln Ile Gly Asp Leu Val Gly	
	145 150 155 160	
	gaa gcg atg aac aag gtc ggc cac gac agc gtg gtc agc gtc aag gaa	528
	Glu Ala Met Asn Lys Val Gly His Asp Ser Val Val Ser Val Lys Glu	
	165 170 175	
10	tcc tcc acg ctg ggc acc gag ttg gag ttc acc gaa ggt att ggc ttc	576
	Ser Ser Thr Leu Gly Thr Glu Leu Glu Phe Thr Glu Gly Ile Gly Phe	
	180 185 190	
15	cac aaa ggc ttc ttg tcg gca tac ttc gtt acc gac ttc gat aac cag	624
	His Lys Gly Phe Leu Ser Ala Tyr Phe Val Thr Asp Phe Asp Asn Gln	
	195 200 205	
	cag gcg gtg ctc gag gac gcg ttg atc ctg cta cac caa gac aag atc	672
	Gln Ala Val Leu Glu Asp Ala Leu Ile Leu Leu His Gln Asp Lys Ile	
	210 215 220	
20	agc tcg ctt ccc gat ctg ttg cca ttg ctg gaa aag gtt gca gga acg	720
	Ser Ser Leu Pro Asp Leu Leu Pro Leu Leu Glu Lys Val Ala Gly Thr	
	225 230 235 240	
	ggg aag cca cta ctg atc gtg gct gaa gac gtg gag ggc gaa gcg ttg	768
	Gly Lys Pro Leu Leu Ile Val Ala Glu Asp Val Glu Gly Glu Ala Leu	
	245 250 255	
25	gcg acg ctg gtc gtc aac gcg att cgc aag acg ttg aaa gcg gtc gcg	816
	Ala Thr Leu Val Val Asn Ala Ile Arg Lys Thr Leu Lys Ala Val Ala	
	260 265 270	
30	gtc aag ggg ccg tac ttc ggt gac cgc cgt aag gcg ttc ctt gag gac	864
	Val Lys Gly Pro Tyr Phe Gly Asp Arg Arg Lys Ala Phe Leu Glu Asp	
	275 280 285	
	ctg gcg gtg gtg acg ggt ggc cac gtg gtc aac ccc gac gcc gcc att	912
	Leu Ala Val Val Thr Gly Gly His Val Val Asn Pro Asp Ala Gly Ile	
	290 295 300	
35	gtg ctg cgc gag gtg ggc ttg gag gtg ctg ggc tcg gcc cga cgc gtg	960
	Val Leu Arg Glu Val Gly Leu Glu Val Leu Gly Ser Ala Arg Arg Val	
	305 310 315 320	
	gtg gtc agc aag gac gac acg gtc att gtc gac ggc ggc ggc acc gca	1008
	Val Val Ser Lys Asp Asp Thr Val Ile Val Asp Gly Gly Gly Thr Ala	
	325 330 335	
40	gaa gcg gtg gcc aac cgg gcg aac cac ttg cgt gcc gag atc gac aag	1056
	Glu Ala Val Ala Asn Arg Ala Asn His Leu Arg Ala Glu Ile Asp Lys	
	340 345 350	
45	agc gat tcg gat tgg gat cgg gaa aag ctt ggc gag cgg ctg gcc aaa	1104
	Ser Asp Ser Asp Trp Asp Arg Glu Lys Leu Gly Glu Arg Leu Ala Lys	
	355 360 365	
	ctg gcc ggc ggg gtt gct gtc atc aag gtg ggt gcc gcc acc gac acc	1152

Leu Ala Gly Gly Val Ala Val Ile Lys Val Gly Ala Ala Thr Asp Thr  
 370 375 380

5 gca ctc aag gag cgc aag gaa agc gtc gag gat gcg gtc gcg gcc gcc 1200  
 Ala Leu Lys Glu Arg Lys Glu Ser Val Glu Asp Ala Val Ala Ala Ala  
 385 390 395 400

aag gcc gcg gtc gag gag ggc atc gtc cct ggt ggg gga gcc tcg ctc 1248  
 Lys Ala Ala Val Glu Glu Gly Ile Val Pro Gly Gly Gly Ala Ser Leu  
 405 410 415

10 atc cac cag gcc cgc aag gcg ctg acc gaa ctg cgt gcg tcg ctg acc 1296  
 Ile His Gln Ala Arg Lys Ala Leu Thr Glu Leu Arg Ala Ser Leu Thr  
 420 425 430

ggt gac gag gtc ctc ggt gtc gac gtg ttc tcc gaa gcc ctt gcc gcg 1344  
 Gly Asp Glu Val Leu Gly Val Asp Val Phe Ser Glu Ala Leu Ala Ala  
 435 440 445

15 ccg ttg ttc tgg atc gcc gcc aac gct ggc ttg gac ggc tcg gtg gtg 1392  
 Pro Leu Phe Trp Ile Ala Ala Asn Ala Gly Leu Asp Gly Ser Val Val  
 450 455 460

20 gtc aac aag gtc agc gag cta ccc gcc ggg cat ggg ctg aac gtg aac 1440  
 Val Asn Lys Val Ser Glu Leu Pro Ala Gly His Gly Leu Asn Val Asn  
 465 470 475 480

acc ctg agc tat ggt gac ttg gcc gct gac ggc gtc atc gac ccg gtc 1488  
 Thr Leu Ser Tyr Gly Asp Leu Ala Ala Asp Gly Val Ile Asp Pro Val  
 485 490 495

25 aag gtg act agg tcg gcg gtg ttg aac gcg tca tcg gtt gcc cgg atg 1536  
 Lys Val Thr Arg Ser Ala Val Leu Asn Ala Ser Ser Val Ala Arg Met  
 500 505 510

gta ctc acc acc gag acg gtc gtg gtc gac aag ccg gcc aag gca gaa 1584  
 Val Leu Thr Thr Glu Thr Val Val Val Asp Lys Pro Ala Lys Ala Glu  
 515 520 525

30 gat cac gac cat cac cac ggg cac gcg cac tga 1617  
 Asp His Asp His His His Gly His Ala His  
 530 535

<210> 2  
 <211> 538  
 35 <212> PRT  
 <213> Mycobacterium tuberculosis

<400> 2  
 Ser Lys Leu Ile Glu Tyr Asp Glu Thr Ala Arg Arg Ala Met Glu Val  
 1 5 10 15  
 40 Gly Met Asp Lys Leu Ala Asp Thr Val Arg Val Thr Leu Gly Pro Arg  
 20 25 30  
 Gly Arg His Val Val Leu Ala Lys Ala Phe Gly Gly Pro Thr Val Thr  
 35 40 45  
 Asn Asp Gly Val Thr Val Ala Arg Glu Ile Glu Leu Glu Asp Pro Phe  
 50 55 60  
 45 Glu Asp Leu Gly Ala Gln Leu Val Lys Ser Val Ala Thr Lys Thr Asn  
 65 70 75 80  
 Asp Val Ala Gly Asp Gly Thr Thr Thr Ala Thr Ile Leu Ala Gln Ala

				85				90				95		
	Leu	Ile	Lys	Gly	Gly	Leu	Arg	Leu	Val	Ala	Ala	Gly	Val	Asn
				100					105				110	Pro
	Ala	Leu	Gly	Val	Gly	Ile	Gly	Lys	Ala	Ala	Asp	Ala	Val	Phe
5				115				120					125	Glu
	Leu	Leu	Ala	Ser	Ala	Thr	Pro	Val	Ser	Gly	Lys	Thr	Gly	Ile
				130				135					140	Ala
	Val	Ala	Thr	Val	Ser	Ser	Arg	Asp	Glu	Gln	Ile	Gly	Asp	Leu
														Val
10	Glu	Ala	Met	Asn	Lys	Val	Gly	His	Asp	Ser	Val	Val	Ser	Val
														Lys
					165				170					175
	Ser	Ser	Thr	Leu	Gly	Thr	Glu	Leu	Glu	Phe	Thr	Glu	Gly	Ile
														Gly
					180				185					190
	His	Lys	Gly	Phe	Leu	Ser	Ala	Tyr	Phe	Val	Thr	Asp	Phe	Asp
15														Asn
					195			200					205	Gln
	Gln	Ala	Val	Leu	Glu	Asp	Ala	Leu	Ile	Leu	Leu	His	Gln	Asp
														Lys
					210			215					220	Ile
	Ser	Ser	Leu	Pro	Asp	Leu	Leu	Pro	Leu	Leu	Glu	Lys	Val	Ala
														Gly
														Thr
														240
20	Gly	Lys	Pro	Leu	Leu	Ile	Val	Ala	Glu	Asp	Val	Glu	Gly	Glu
														Ala
														Leu
														255
	Ala	Thr	Leu	Val	Val	Asn	Ala	Ile	Arg	Lys	Thr	Leu	Lys	Ala
														Val
														Ala
														270
	Val	Lys	Gly	Pro	Tyr	Phe	Gly	Asp	Arg	Arg	Lys	Ala	Phe	Leu
25														Glu
														Asp
	Leu	Ala	Val	Val	Thr	Gly	Gly	His	Val	Val	Asn	Pro	Asp	Ala
														Gly
														Ile
														300
	Val	Leu	Arg	Glu	Val	Gly	Leu	Glu	Val	Leu	Gly	Ser	Ala	Arg
														Arg
														Val
														320
30	Val	Val	Ser	Lys	Asp	Asp	Thr	Val	Ile	Val	Asp	Gly	Gly	Gly
														Thr
														Ala
														335
	Glu	Ala	Val	Ala	Asn	Arg	Ala	Asn	His	Leu	Arg	Ala	Glu	Ile
														Asp
														Lys
														350
	Ser	Asp	Ser	Asp	Trp	Asp	Arg	Glu	Lys	Leu	Gly	Glu	Arg	Leu
35														Ala
														Lys
	Leu	Ala	Gly	Gly	Val	Ala	Val	Ile	Lys	Val	Gly	Ala	Ala	Thr
														Asp
														Thr
														380
	Ala	Leu	Lys	Glu	Arg	Lys	Glu	Ser	Val	Glu	Asp	Ala	Val	Ala
														Ala
														400
40	Lys	Ala	Ala	Val	Glu	Gly	Ile	Val	Pro	Gly	Gly	Gly	Ala	Ser
														Leu
														415
	Ile	His	Gln	Ala	Arg	Lys	Ala	Leu	Thr	Glu	Leu	Arg	Ala	Ser
														Leu
														Thr
														430
	Gly	Asp	Glu	Val	Leu	Gly	Val	Asp	Val	Phe	Ser	Glu	Ala	Leu
45														Ala
														445
	Pro	Leu	Phe	Trp	Ile	Ala	Ala	Asn	Ala	Gly	Leu	Asp	Gly	Ser
														Val
														Val
														460
	Val	Asn	Lys	Val	Ser	Glu	Leu	Pro	Ala	Gly	His	Gly	Leu	Asn
														Val
														Asn
														480
50	Thr	Leu	Ser	Tyr	Gly	Asp	Leu	Ala	Ala	Asp	Gly	Val	Ile	Asp
														Pro
														Val
														495
	Lys	Val	Thr	Arg	Ser	Ala	Val	Leu	Asn	Ala	Ser	Ser	Val	Ala
														Arg
														Met
														510
	Val	Leu	Thr	Thr	Glu	Thr	Val	Val	Val	Asp	Lys	Pro	Ala	Lys
55														Ala
														Glu
														525
	Asp	His	Asp	His	His	His	Gly	His	Ala	His				
														535
														530

<211> 1560  
 <212> DNA  
 <213> Mycobacterium tuberculosis  
 <220>  
 5 <221> CDS  
 <222> (1)..(1560)

<220>  
 <221> mat\_peptide  
 <222> (1)..(1560)

10 <400> 3  
 gcg gcc atg tgg cgc cgc aga ccg ttg agc tcg gcg ctg ctg tcc ttc 48  
 Ala Ala Met Trp Arg Arg Pro Leu Ser Ser Ala Leu Leu Ser Phe  
 1 5 10 15

15 ggg ttg ctg ctc ggc gga ctg ctc cta gca gcg ccc ccg ttg gcc ggc 96  
 Gly Leu Leu Leu Gly Gly Leu Leu Leu Ala Ala Pro Pro Leu Ala Gly  
 20 25 30

gcg act gaa gaa ccc ggc gcc ggc caa acc ccg ggt gcg ccg gtc gtg 144  
 Ala Thr Glu Glu Pro Gly Ala Gly Gln Thr Pro Gly Ala Pro Val Val  
 35 40 45

20 gcg ccg caa cag agt tgg aac agc tgc cgc gag ttc atc gcc gac acc 192  
 Ala Pro Gln Gln Ser Trp Asn Ser Cys Arg Glu Phe Ile Ala Asp Thr  
 50 55 60

agc gaa att cgc act gca cgc tgc gcg acg gtg tcc gtc ccc gtc gac 240  
 Ser Glu Ile Arg Thr Ala Arg Cys Ala Thr Val Ser Val Pro Val Asp  
 25 65 70 75 80

tac gac caa ccc ggt ggg aca caa gcg aag ttg gcg gtg atc cgc gtc 288  
 Tyr Asp Gln Pro Gly Gly Thr Gln Ala Lys Leu Ala Val Ile Arg Val  
 85 90 95

ccc gcg acg gga cag cga ttc gga gca ctg ctg gtc aat cct ggg gga 336  
 Pro Ala Thr Gly Gln Arg Phe Gly Ala Leu Leu Val Asn Pro Gly Gly  
 100 105 110

ccc ggg gcg tcg gcg gtc gac atg gtc gcc gct atg gca ccc gcg atc 384  
 Pro Gly Ala Ser Ala Val Asp Met Val Ala Ala Met Ala Pro Ala Ile  
 115 120 125

35 gcc gac acc gac att ctc cgc cac ttc gac ctg gtg ggc ttc gac ccg 432  
 Ala Asp Thr Asp Ile Leu Arg His Phe Asp Leu Val Gly Phe Asp Pro  
 130 135 140

aga ggg gtc ggc cac tcg acc cct gcg ttg cgg tgt cgc acc gac gcc 480  
 Arg Gly Val Gly His Ser Thr Pro Ala Leu Arg Cys Arg Thr Asp Ala  
 40 145 150 155 160

gag ttc gac gcg tac cgg cgc gat ccg atg gcc gac tac agt ccg gcc 528  
 Glu Phe Asp Ala Tyr Arg Arg Asp Pro Met Ala Asp Tyr Ser Pro Ala  
 165 170 175

ggc gtc acc cac gtc gaa cag gtc tac cgg cag ttg gcc cag gac tgt 576  
 Gly Val Thr His Val Glu Gln Val Tyr Arg Gln Leu Ala Gln Asp Cys  
 180 185 190

gtt gac cgg atg ggc ttc agc ttc ttg gcc aat atc ggt acc gcg tcc 624

	Val	Asp	Arg	Met	Gly	Phe	Ser	Phe	Leu	Ala	Asn	Ile	Gly	Thr	Ala	Ser	
			195					200					205				
5	gtc	gca	cgg	gac	atg	gac	atg	gtt	cgc	caa	gcg	tta	ggt	gac	gat	cag	672
	Val	Ala	Arg	Asp	Met	Asp	Met	Val	Arg	Gln	Ala	Leu	Gly	Asp	Asp	Gln	
		210					215					220					
	atc	aac	tac	ctc	gga	tac	agc	tac	ggc	acc	aag	ttg	ggc	acc	gct	tac	720
	Ile	Asn	Tyr	Leu	Gly	Tyr	Ser	Tyr	Gly	Thr	Lys	Leu	Gly	Thr	Ala	Tyr	
	225					230					235					240	
10	ctg	gaa	cgg	ttc	ggt	act	cat	gtg	cgg	gcg	atg	gtc	ctc	gac	ggc	gct	768
	Leu	Glu	Arg	Phe	Gly	Thr	His	Val	Arg	Ala	Met	Val	Leu	Asp	Gly	Ala	
					245					250					255		
	atc	gat	cca	gcc	gtt	agc	cca	atc	gag	gaa	agc	atc	agc	caa	atg	gcg	816
	Ile	Asp	Pro	Ala	Val	Ser	Pro	Ile	Glu	Glu	Ser	Ile	Ser	Gln	Met	Ala	
				260					265						270		
15	gga	ttt	cag	acc	gct	ttc	aat	gac	tac	gcc	gcc	gac	tgc	gcc	cgc	tcg	864
	Gly	Phe	Gln	Thr	Ala	Phe	Asn	Asp	Tyr	Ala	Ala	Asp	Cys	Ala	Arg	Ser	
				275				280					285				
20	ccg	gcc	tgc	cct	ctg	ggc	acc	gac	tcg	gcc	cag	tgg	gtc	aac	cgc	tac	912
	Pro	Ala	Cys	Pro	Leu	Gly	Thr	Asp	Ser	Ala	Gln	Trp	Val	Asn	Arg	Tyr	
		290					295					300					
	cac	gcc	ctg	gtt	gac	ccg	ctg	gtg	cag	aag	ccg	ggt	aag	acg	tcg	gat	960
	His	Ala	Leu	Val	Asp	Pro	Leu	Val	Gln	Lys	Pro	Gly	Lys	Thr	Ser	Asp	
	305					310					315					320	
25	cca	cgt	ggc	ctg	agc	tac	gcc	gac	gcg	acg	acg	ggc	acc	atc	aac	gcg	1008
	Pro	Arg	Gly	Leu	Ser	Tyr	Ala	Asp	Ala	Thr	Thr	Gly	Thr	Ile	Asn	Ala	
					325					330					335		
	ctg	tac	agc	cct	cag	cgc	tgg	aag	tac	ctg	acc	agt	ggt	ctg	ctg	ggg	1056
	Leu	Tyr	Ser	Pro	Gln	Arg	Trp	Lys	Tyr	Leu	Thr	Ser	Gly	Leu	Leu	Gly	
				340				345						350			
30	ctg	cag	cgc	ggc	agc	gac	gcc	ggc	gac	ttg	ctg	gtg	ctt	gcc	gac	gac	1104
	Leu	Gln	Arg	Gly	Ser	Asp	Ala	Gly	Asp	Leu	Leu	Val	Leu	Ala	Asp	Asp	
			355					360					365				
35	tat	gac	ggc	cgg	gat	gca	gac	ggg	cac	tac	agc	aac	gac	cag	gac	gcg	1152
	Tyr	Asp	Gly	Arg	Asp	Ala	Asp	Gly	His	Tyr	Ser	Asn	Asp	Gln	Asp	Ala	
		370					375					380					
	ttc	aac	gcg	gtc	cgg	tgc	gtc	tat	gcg	ccc	aca	ccg	gcc	gat	cca	gcg	1200
	Phe	Asn	Ala	Val	Arg	Cys	Val	Tyr	Ala	Pro	Thr	Pro	Ala	Asp	Pro	Ala	
	385					390					395					400	
40	gcc	tgg	gtg	gcc	gcc	gac	caa	cgg	atc	cgt	cag	gtc	gcc	ccg	ttc	ctt	1248
	Ala	Trp	Val	Ala	Ala	Asp	Gln	Arg	Ile	Arg	Gln	Val	Ala	Pro	Phe	Leu	
					405					410					415		
	agc	tac	ggg	cag	ttc	acc	gga	tcc	gcc	ccc	cgc	gat	ctg	tgc	gcg	ctg	1296
	Ser	Tyr	Gly	Gln	Phe	Thr	Gly	Ser	Ala	Pro	Arg	Asp	Leu	Cys	Ala	Leu	
				420					425					430			
45	tgg	ccg	gtg	ccg	gca	acg	tcg	acg	ccg	cac	ccc	gcg	gcg	ccg	gcc	ggg	1344
	Trp	Pro	Val	Pro	Ala	Thr	Ser	Thr	Pro	His	Pro	Ala	Ala	Pro	Ala	Gly	



	435	440	445	
	gct ggc aag gtc gtc gtg gtg tcc acc acc cac gac ccg gcc act ccg			1392
	Ala Gly Lys Val Val Val Val Ser Thr Thr His Asp Pro Ala Thr Pro			
	450	455	460	
5	tat cag tcc ggg gta gac ctg gcc cgc cag ctg ggc gca ccg ctg atc			1440
	Tyr Gln Ser Gly Val Asp Leu Ala Arg Gln Leu Gly Ala Pro Leu Ile			
	465	470	475	480
	acc ttc gac ggc acc caa cac act gcg gtg ttc gat ggc aac cag tgt			1488
	Thr Phe Asp Gly Thr Gln His Thr Ala Val Phe Asp Gly Asn Gln Cys			
10		485	490	495
	gtg gac tct gcg gtg atg cac tat ttt ctc gac ggg acc ttg ccg ccg			1536
	Val Asp Ser Ala Val Met His Tyr Phe Leu Asp Gly Thr Leu Pro Pro			
		500	505	510
	acg agt ctg cgg tgc gcg ccc tga			1560
15	Thr Ser Leu Arg Cys Ala Pro			
	515	520		
	<210> 4			
	<211> 519			
	<212> PRT			
20	<213> Mycobacterium tuberculosis			
	<400> 4			
	Ala Ala Met Trp Arg Arg Arg Pro Leu Ser Ser Ala Leu Leu Ser Phe			
	1 5 10 15			
25	Gly Leu Leu Leu Gly Gly Leu Leu Leu Ala Ala Pro Pro Leu Ala Gly			
	20 25 30			
	Ala Thr Glu Glu Pro Gly Ala Gly Gln Thr Pro Gly Ala Pro Val Val			
	35 40 45			
	Ala Pro Gln Gln Ser Trp Asn Ser Cys Arg Glu Phe Ile Ala Asp Thr			
	50 55 60			
30	Ser Glu Ile Arg Thr Ala Arg Cys Ala Thr Val Ser Val Pro Val Asp			
	65 70 75 80			
	Tyr Asp Gln Pro Gly Thr Gln Ala Lys Leu Ala Val Ile Arg Val			
	85 90 95			
	Pro Ala Thr Gly Gln Arg Phe Gly Ala Leu Leu Val Asn Pro Gly Gly			
35	100 105 110			
	Pro Gly Ala Ser Ala Val Asp Met Val Ala Ala Met Ala Pro Ala Ile			
	115 120 125			
	Ala Asp Thr Asp Ile Leu Arg His Phe Asp Leu Val Gly Phe Asp Pro			
	130 135 140			
40	Arg Gly Val Gly His Ser Thr Pro Ala Leu Arg Cys Arg Thr Asp Ala			
	145 150 155 160			
	Glu Phe Asp Ala Tyr Arg Arg Asp Pro Met Ala Asp Tyr Ser Pro Ala			
	165 170 175			
	Gly Val Thr His Val Glu Gln Val Tyr Arg Gln Leu Ala Gln Asp Cys			
45	180 185 190			
	Val Asp Arg Met Gly Phe Ser Phe Leu Ala Asn Ile Gly Thr Ala Ser			
	195 200 205			
	Val Ala Arg Asp Met Asp Met Val Arg Gln Ala Leu Gly Asp Asp Gln			
	210 215 220			
50	Ile Asn Tyr Leu Gly Tyr Ser Tyr Gly Thr Lys Leu Gly Thr Ala Tyr			
	225 230 235 240			
	Leu Glu Arg Phe Gly Thr His Val Arg Ala Met Val Leu Asp Gly Ala			
	245 250 255			
	Ile Asp Pro Ala Val Ser Pro Ile Glu Glu Ser Ile Ser Gln Met Ala			

35  
40  
45  
50

	tac gtc gtc gcc tat ctc ggc ggc ttg cag gcc ggg cgc atc gcc gtg	192
	Tyr Val Val Ala Tyr Leu Gly Ala Leu Gln Ala Gly Arg Ile Ala Val	
	50 55 60	
5	ccg ctt tcg gtt cca caa ggc ggc gtt acc gat gaa cgt tcc gat tcg	240
	Pro Leu Ser Val Pro Gln Gly Gly Val Thr Asp Glu Arg Ser Asp Ser	
	65 70 75 80	
	gta ctg agt gat tcg tcg ccg gtg gcc att ctc act aca tcg tct gcc	288
	Val Leu Ser Asp Ser Ser Pro Val Ala Ile Leu Thr Thr Ser Ser Ala	
	85 90 95	
10	gtg gac gac gtc gtg caa cat gtt gcg cgg cgg ccc ggg gaa tcc ccg	336
	Val Asp Asp Val Val Gln His Val Ala Arg Arg Pro Gly Glu Ser Pro	
	100 105 110	
	cca tca att atc gaa gtt gat ttg ctc gat ctg gac gct ccg aat ggg	384
	Pro Ser Ile Ile Glu Val Asp Leu Leu Asp Leu Asp Ala Pro Asn Gly	
15	115 120 125	
	tat acc ttc aaa gaa gac gag tat cca tct acc gcg tat ttg caa tac	432
	Tyr Thr Phe Lys Glu Asp Glu Tyr Pro Ser Thr Ala Tyr Leu Gln Tyr	
	130 135 140	
20	acc tcc ggg tcc acc cgc acg ccc gct ggc gtg gtg atg tcc cat cag	480
	Thr Ser Gly Ser Thr Arg Thr Pro Ala Gly Val Val Met Ser His Gln	
	145 150 155 160	
	aac gtt cgg gtt aat ttc gaa cag ctg atg tct ggc tac ttt gcg gat	528
	Asn Val Arg Val Asn Phe Glu Gln Leu Met Ser Gly Tyr Phe Ala Asp	
	165 170 175	
25	acc gac ggg att cca ccg cca aat tcc gca ctc gta tcc tgg cta ccc	576
	Thr Asp Gly Ile Pro Pro Pro Asn Ser Ala Leu Val Ser Trp Leu Pro	
	180 185 190	
	ttc tac cac gac atg ggt ttg gta ata gga att tgc gca cca att ctg	624
	Phe Tyr His Asp Met Gly Leu Val Ile Gly Ile Cys Ala Pro Ile Leu	
30	195 200 205	
	ggg gga tac ccc gcg gtg ctc acc agc ccg gtg tcg ttc ctg cag cgc	672
	Gly Gly Tyr Pro Ala Val Leu Thr Ser Pro Val Ser Phe Leu Gln Arg	
	210 215 220	
35	ccg gcc cgg tgg atg cac ttg atg gcc agc gat ttt cac gcc ttt tcg	720
	Pro Ala Arg Trp Met His Leu Met Ala Ser Asp Phe His Ala Phe Ser	
	225 230 235 240	
	gca gca ccg aat ttc gcc ttt gaa cta gcg gca cga aga aca acc gac	768
	Ala Ala Pro Asn Phe Ala Phe Glu Leu Ala Ala Arg Arg Thr Thr Asp	
	245 250 255	
40	gac gac atg gcc ggg cgt gac ctc ggc aac ata ctg acc atc ctc agc	816
	Asp Asp Met Ala Gly Arg Asp Leu Gly Asn Ile Leu Thr Ile Leu Ser	
	260 265 270	
45	ggg agc gag cgg gta cag gcc gcg acg atc aag cgc ttc gcc gac cgc	864
	Gly Ser Glu Arg Val Gln Ala Ala Thr Ile Lys Arg Phe Ala Asp Arg	
	275 280 285	

ttt gct cgc ttc aat ctg cag gag agg gtg aaa gct taa  
Phe Ala Arg Phe Asn Leu Gln Glu Arg Val Lys Ala  
290 295 300

903

5 <210> 6  
<211> 300  
<212> PRT  
<213> Mycobacterium tuberculosis

<400> 6  
10 Asp Tyr Glu Gln Asp Trp Asp Gly Val Ala Ile Thr Leu Thr Arg Ser  
1 5 10 15  
Gln Leu Tyr Arg Arg Thr Leu Asn Val Ala Gln Glu Leu Ser Arg Cys  
20 25 30  
Gly Ser Thr Gly Asp Arg Val Val Ile Ser Ala Pro Gln Gly Leu Glu  
35 40 45  
15 Tyr Val Val Ala Tyr Leu Gly Ala Leu Gln Ala Gly Arg Ile Ala Val  
50 55 60  
Pro Leu Ser Val Pro Gln Gly Gly Val Thr Asp Glu Arg Ser Asp Ser  
65 70 75 80  
Val Leu Ser Asp Ser Ser Pro Val Ala Ile Leu Thr Thr Ser Ser Ala  
85 90 95  
20 Val Asp Asp Val Val Gln His Val Ala Arg Arg Pro Gly Glu Ser Pro  
100 105 110  
Pro Ser Ile Ile Glu Val Asp Leu Leu Asp Leu Asp Ala Pro Asn Gly  
115 120 125  
25 Tyr Thr Phe Lys Glu Asp Glu Tyr Pro Ser Thr Ala Tyr Leu Gln Tyr  
130 135 140  
Thr Ser Gly Ser Thr Arg Thr Pro Ala Gly Val Val Met Ser His Gln  
145 150 155 160  
Asn Val Arg Val Asn Phe Glu Gln Leu Met Ser Gly Tyr Phe Ala Asp  
165 170 175  
30 Thr Asp Gly Ile Pro Pro Pro Asn Ser Ala Leu Val Ser Trp Leu Pro  
180 185 190  
Phe Tyr His Asp Met Gly Leu Val Ile Gly Ile Cys Ala Pro Ile Leu  
195 200 205  
35 Gly Gly Tyr Pro Ala Val Leu Thr Ser Pro Val Ser Phe Leu Gln Arg  
210 215 220  
Pro Ala Arg Trp Met His Leu Met Ala Ser Asp Phe His Ala Phe Ser  
225 230 235 240  
Ala Ala Pro Asn Phe Ala Phe Glu Leu Ala Ala Arg Arg Thr Thr Asp  
245 250 255  
40 Asp Asp Met Ala Gly Arg Asp Leu Gly Asn Ile Leu Thr Ile Leu Ser  
260 265 270  
Gly Ser Glu Arg Val Gln Ala Ala Thr Ile Lys Arg Phe Ala Asp Arg  
275 280 285  
45 Phe Ala Arg Phe Asn Leu Gln Glu Arg Val Lys Ala  
290 295 300

50 <210> 7  
<211> 432  
<212> DNA  
<213> Mycobacterium tuberculosis

<220>  
<221> CDS  
<222> (1)..(432)

<220>  
<221> mat\_peptide  
<222> (1)..(432)

<400> 7

5	gcc acc acc ctt ccc gtt cag cgc cac ccg cgg tcc ctc ttc ccc gag	48
	Ala Thr Thr Leu Pro Val Gln Arg His Pro Arg Ser Leu Phe Pro Glu	
	1 5 10 15	
10	ttt tct gag ctg ttc gcg gcc ttc ccg tca ttc gcc gga ctc cgg ccc	96
	Phe Ser Glu Leu Phe Ala Ala Phe Pro Ser Phe Ala Gly Leu Arg Pro	
	20 25 30	
	acc ttc gac acc cgg ttg atg cgg ctg gaa gac gag atg aaa gag ggg	144
	Thr Phe Asp Thr Arg Leu Met Arg Leu Glu Asp Glu Met Lys Glu Gly	
	35 40 45	
15	cgc tac gag gta cgc gcg gag ctt ccc ggg gtc gac ccc gac aag gac	192
	Arg Tyr Glu Val Arg Ala Glu Leu Pro Gly Val Asp Pro Asp Lys Asp	
	50 55 60	
	gtc cac att atg gtc cgc gat ggt cag ctg acc atc aag gcc gag cgc	240
	Val His Ile Met Val Arg Asp Gly Gln Leu Thr Ile Lys Ala Glu Arg	
	65 70 75 80	
20	acc gag cag aag gac tta gac ggt cgc tcg gaa ttc gcg tac ggt tcc	288
	Thr Glu Gln Lys Asp Leu Asp Gly Arg Ser Glu Phe Ala Tyr Gly Ser	
	85 90 95	
25	ttc gtt cgc acg gtg tcg ctg ccg gta ggt gct gac gag gac gac att	336
	Phe Val Arg Thr Val Ser Leu Pro Val Gly Ala Asp Glu Asp Asp Ile	
	100 105 110	
	aag gcc acc tac gac aag ggc att ctt act gtg tcg gtg gcg gtt tcg	384
	Lys Ala Thr Tyr Asp Lys Gly Ile Leu Thr Val Ser Val Ala Val Ser	
	115 120 125	
30	gaa ggg aag cca acc gaa aag cac att cag atc cgg tcc acc aac tga	432
	Glu Gly Lys Pro Thr Glu Lys His Ile Gln Ile Arg Ser Thr Asn	
	130 135 140	

<210> 8

<211> 143

<212> PRT

35 <213> Mycobacterium tuberculosis

<400> 8

	Ala Thr Thr Leu Pro Val Gln Arg His Pro Arg Ser Leu Phe Pro Glu	
	1 5 10 15	
40	Phe Ser Glu Leu Phe Ala Ala Phe Pro Ser Phe Ala Gly Leu Arg Pro	
	20 25 30	
	Thr Phe Asp Thr Arg Leu Met Arg Leu Glu Asp Glu Met Lys Glu Gly	
	35 40 45	
	Arg Tyr Glu Val Arg Ala Glu Leu Pro Gly Val Asp Pro Asp Lys Asp	
	50 55 60	
45	Val His Ile Met Val Arg Asp Gly Gln Leu Thr Ile Lys Ala Glu Arg	
	65 70 75 80	
	Thr Glu Gln Lys Asp Leu Asp Gly Arg Ser Glu Phe Ala Tyr Gly Ser	
	85 90 95	
	Phe Val Arg Thr Val Ser Leu Pro Val Gly Ala Asp Glu Asp Asp Ile	

```

      100              105              110
Lys Ala Thr Tyr Asp Lys Gly Ile Leu Thr Val Ser Val Ala Val Ser
      115              120              125
Glu Gly Lys Pro Thr Glu Lys His Ile Gln Ile Arg Ser Thr Asn
5      130              135              140

<210> 9
<211> 1161
<212> DNA
<213> Mycobacterium tuberculosis

10 <220>
    <221> CDS
    <222> (1)..(1161)

    <220>
    <221> mat_peptide
15 <222> (1)..(1161)

    <400> 9
aat tcg atg cca gtc ccg ccg gcg cca cca gcg ccg ccg tca ccg atc      48
Asn Ser Met Pro Val Pro Pro Ala Pro Pro Ala Pro Pro Ser Pro Ile
      1              5              10              15

20 aac ccg ccg gtg ccg ccg gtg ccg ccg cta ccg gcc gcg ccc ccg acg      96
Asn Pro Pro Val Pro Pro Val Pro Pro Leu Pro Ala Ala Pro Arg Thr
      20              25              30

    ctg tcg ccg ccg gta ccg ccg gcg ccg ccg tcg ccg atc agc ttg gcg      144
Leu Ser Pro Pro Val Pro Pro Ala Pro Pro Ser Pro Ile Ser Leu Ala
      35              40              45

25 gcc ccg ccg ctg cca ccg gac ccg ccg atg ccg ccg gcc att tgg tcc      192
Ala Pro Pro Leu Pro Pro Asp Pro Pro Met Pro Pro Ala Ile Trp Ser
      50              55              60

    gca ctg gag gcg ccg aac cct ccg gtg ccc ccg gcg ccg ccg gga ccg      240
Ala Leu Glu Ala Pro Asn Pro Pro Val Pro Pro Ala Pro Pro Gly Pro
      65              70              75              80

    aac agt gcg ccg gca ccg ccg atg ccg ccg acg cct cct ttg ccg ccg      288
Asn Ser Ala Pro Ala Pro Pro Met Pro Pro Thr Pro Pro Leu Pro Pro
      85              90              95

35 gtg ccg ccg ggg tcg ggc gcg ccg aga ccg gtt ccg gcg gtg ccg cca      336
Val Pro Pro Gly Ser Gly Ala Pro Arg Pro Val Pro Ala Val Pro Pro
      100              105              110

    atg ccg cca gcg ccg aag agg atg ccg gcg ttg ccg ccc gcc ccg ccg      384
Met Pro Pro Ala Pro Lys Arg Met Pro Ala Leu Pro Pro Ala Pro Pro
      115              120              125

    gcc ccg ccc tca ccg ccc acg agt tgg tta gcg gtg cca gtt ccg ccg      432
Ala Pro Pro Ser Pro Pro Thr Ser Trp Leu Ala Val Pro Val Pro Pro
      130              135              140

45 gtg ccg ccg gtc ccg ccg ttg ccg gtg aag atg ccg ccg tcg cct ccg      480
Val Pro Pro Val Pro Pro Leu Pro Val Lys Met Pro Pro Ser Pro Pro
      145              150              155              160

```

	gtg ccg ccg ttc cct ccg gcc gag ccg gag act ccg aac ccg ccg gcg	528
	Val Pro Pro Phe Pro Pro Ala Glu Pro Glu Thr Pro Asn Pro Pro Ala	
	165 170 175	
5	ccg ccg gca ccg cca ttg gag aac agc ccg ccg ccc ccg ccg gtg ccg	576
	Pro Pro Ala Pro Pro Leu Glu Asn Ser Pro Pro Pro Pro Pro Val Pro	
	180 185 190	
	ccg gtg cca ccg gtg ccc ccg ttg acg ctc aac ccg ccg gtg ccg ccg	624
	Pro Val Pro Pro Val Pro Pro Leu Thr Leu Asn Pro Pro Val Pro Pro	
	195 200 205	
10	gca ccg ccg gcg gcc aac acc tcg aac agc ccg ctg cga ccg ccg gcc	672
	Ala Pro Pro Ala Ala Asn Thr Ser Asn Ser Pro Leu Arg Pro Pro Ala	
	210 215 220	
	ccg ccg gcg cca ccg ttg aag cct ggc ccg ccg gcc ccg ccg atg cca	720
15	Pro Pro Ala Pro Pro Leu Lys Pro Gly Pro Pro Ala Pro Pro Met Pro	
	225 230 235 240	
	ccg gct ccg aac agc ccg gcc gcc ccg ccg tcg ccg ccg agc ccg cct	768
	Pro Ala Pro Asn Ser Pro Ala Ala Pro Pro Ser Pro Pro Ser Pro Pro	
	245 250 255	
20	gtg ccg gtg ttc ccg act ccg ccg ggc ccc ccg gcg ccg ccg gag ccg	816
	Val Pro Val Phe Pro Thr Pro Pro Gly Pro Pro Ala Pro Pro Glu Pro	
	260 265 270	
	aac agc agc ccg ccg gcc ccg ccg gcc ccg cca gcc gcg ccg ttg ccc	864
	Asn Ser Ser Ser Pro Pro Ala Pro Pro Ala Pro Pro Ala Pro Leu Pro	
	275 280 285	
25	ggg ccg tca ccc ccg gcc cca ccc gcc ccg ccg ttg ccg aat agc ccc	912
	Gly Pro Ser Pro Pro Ala Pro Pro Ala Pro Pro Leu Pro Asn Ser Pro	
	290 295 300	
	gcg gct cca cct ggg ccg ccg gcc tgg ccg ggc gcc ccg gac ccg ccg	960
30	Ala Ala Pro Pro Gly Pro Pro Ala Trp Pro Gly Ala Pro Asp Pro Pro	
	305 310 315 320	
	gcc ccg ccg ttg ccg tac agc agc ccg ccg gcc ccg ccg gct tgc ccg	1008
	Ala Pro Pro Leu Pro Tyr Ser Ser Pro Pro Ala Pro Pro Ala Cys Pro	
	325 330 335	
35	gtc ccc ggt gcg ccg ttg gcg ccg ttg ccg atc agc gga cgc ccc agc	1056
	Val Pro Gly Ala Pro Leu Ala Pro Leu Pro Ile Ser Gly Arg Pro Ser	
	340 345 350	
	aac agc tgg gtg ggc gtg ttc aca atg ttg agc agg ccc tcc aac ggc	1104
	Asn Ser Trp Val Gly Val Phe Thr Met Leu Ser Arg Pro Ser Asn Gly	
	355 360 365	
40	gcc gcg gcg gcg gcc tca gcg ctc gcg tac gcg cca gcg ccc gca gta	1152
	Ala Ala Ala Ala Ala Ser Ala Leu Ala Tyr Ala Pro Ala Pro Ala Val	
	370 375 380	
	aag gtt tga	1161
45	Lys Val	
	385	

<210> 10  
<211> 386  
<212> PRT  
<213> Mycobacterium tuberculosis

5 <400> 10  
Asn Ser Met Pro Val Pro Pro Ala Pro Pro Ala Pro Pro Ser Pro Ile  
1 5 10 15  
Asn Pro Pro Val Pro Pro Val Pro Pro Leu Pro Ala Ala Pro Arg Thr  
20 25 30  
10 Leu Ser Pro Pro Val Pro Pro Ala Pro Pro Ser Pro Ile Ser Leu Ala  
35 40 45  
Ala Pro Pro Leu Pro Pro Asp Pro Pro Met Pro Pro Ala Ile Trp Ser  
50 55 60  
Ala Leu Glu Ala Pro Asn Pro Pro Val Pro Pro Ala Pro Pro Gly Pro  
15 65 70 75 80  
Asn Ser Ala Pro Ala Pro Pro Met Pro Pro Thr Pro Pro Leu Pro Pro  
85 90 95  
Val Pro Pro Gly Ser Gly Ala Pro Arg Pro Val Pro Ala Val Pro Pro  
100 105 110  
20 Met Pro Pro Ala Pro Lys Arg Met Pro Ala Leu Pro Pro Ala Pro Pro  
115 120 125  
Ala Pro Pro Ser Pro Pro Thr Ser Trp Leu Ala Val Pro Val Pro Pro  
130 135 140  
Val Pro Pro Val Pro Pro Leu Pro Val Lys Met Pro Pro Ser Pro Pro  
25 145 150 155 160  
Val Pro Pro Phe Pro Pro Ala Glu Pro Glu Thr Pro Asn Pro Pro Ala  
165 170 175  
Pro Pro Ala Pro Pro Leu Glu Asn Ser Pro Pro Pro Pro Val Pro  
180 185 190  
30 Pro Val Pro Pro Val Pro Pro Leu Thr Leu Asn Pro Pro Val Pro Pro  
195 200 205  
Ala Pro Pro Ala Ala Asn Thr Ser Asn Ser Pro Leu Arg Pro Pro Ala  
210 215 220  
Pro Pro Ala Pro Pro Leu Lys Pro Gly Pro Pro Ala Pro Pro Met Pro  
35 225 230 235 240  
Pro Ala Pro Asn Ser Pro Ala Ala Pro Pro Ser Pro Pro Ser Pro Pro  
245 250 255  
Val Pro Val Phe Pro Thr Pro Pro Gly Pro Pro Ala Pro Pro Glu Pro  
260 265 270  
40 Asn Ser Ser Pro Pro Ala Pro Pro Ala Pro Pro Ala Ala Pro Leu Pro  
275 280 285  
Gly Pro Ser Pro Pro Ala Pro Pro Ala Pro Pro Leu Pro Asn Ser Pro  
290 295 300  
Ala Ala Pro Pro Gly Pro Pro Ala Trp Pro Gly Ala Pro Asp Pro Pro  
45 305 310 315 320  
Ala Pro Pro Leu Pro Tyr Ser Ser Pro Pro Ala Pro Pro Ala Cys Pro  
325 330 335  
Val Pro Gly Ala Pro Leu Ala Pro Leu Pro Ile Ser Gly Arg Pro Ser  
340 345 350  
50 Asn Ser Trp Val Gly Val Phe Thr Met Leu Ser Arg Pro Ser Asn Gly  
355 360 365  
Ala Ala Ala Ala Ala Ser Ala Leu Ala Tyr Ala Pro Ala Pro Ala Val  
370 375 380  
Lys Val  
55 385



CLAIMS:

1. An isolated polypeptide or a derivative, homologue, analogue or functional equivalent thereof wherein said polypeptide is obtainable from a species of *Mycobacterium* and which polypeptide is immunointeractive with sera from a human, animal or avian species exposed to said species of *Mycobacterium* or its relative or antigenic parts thereof but which polypeptide is substantially not immunointeractive with sera from a human, animal or avian species not prior exposed to said species of *Mycobacterium* or its relative or its antigenic parts.
2. An isolated polypeptide according to claim 1 wherein the species of *Mycobacterium* is selected from *Mycobacterium* is *M. tuberculosis*, *Mycobacterium avium*, *Mycobacterium microti*, *Mycobacterium leprae*, *Mycobacterium lepraemurium*, *Mycobacteria paratuberculosis*, *Mycobacterium ulcerans*, *Mycobacterium marinum*, *Mycobacterium smegmatis*, *Mycobacterium intracellulare*, *Mycobacterium xenopi*, *Mycobacterium chelonae*, *Mycobacterium fortuitum*, *Mycobacterium farcinogenes*, *Mycobacterium flavum*, *Mycobacterium haemophilum*, *Mycobacterium kansasii*, *Mycobacterium phlei*, *Mycobacterium scrofulaceum*, *Mycobacterium senegalense*, *Mycobacterium simiae*, *Mycobacterium thermoresistibile*, and *Mycobacterium xenopi*.
3. An isolated polypeptide according to claim 2 wherein the species of *Mycobacterium* is *M. tuberculosis*.
4. An isolated polypeptide or a derivative, homologue, analogue or functional equivalent thereof wherein said polypeptide is obtainable from *M. tuberculosis* or a related organism and which polypeptide is immunointeractive with sera from a human previously exposed to *M. tuberculosis* or an antigenic extract therefrom but is substantially not immunointeractive with human sera not previously exposed to *M. tuberculosis* or a antigenic extract thereof.
5. An isolated polypeptide according to claim 4 wherein the human exposed to *M. tuberculosis* has active pulmonary or extra-pulmonary tuberculosis.
6. An isolated polypeptide according to claim 4 or 5 wherein the polypeptide has a molecule weight of from about 5 kDa to about 100 kDa.
7. An isolated polypeptide according to claim 6 wherein the molecular weight is selected from about 10 to 20 kDa, 28 to 38 kDa, 38 to 48 kDa, 53 to 63 kDa and 55 to 65 kDa.

8. An isolated polypeptide comprising an amino acid sequence selected from <400>2, <400>4, <400>6, <400>8, <400>10 or an amino acid sequence having at least 60% similarity to any one of said sequences.
9. An isolated polypeptide encoded by a nucleotide sequence selected from <400>1, <400>3, <400>5, <400>7, <400>9 or an nucleotide sequence having at least 60% similarity to any one of said sequences or a nucleotide sequence capable of hybridizing to any one of said sequences under low stringency conditions at 42°C.
10. A method of isolating a polypeptide from *Mycobacterium* species said method comprising culturing cells of said *Mycobacterium* species in a growth medium to increase the number of cells to a sufficient population, harvesting said cells and subjecting said cells to protein extraction techniques to extract protein from said cells, fractionating the extracted protein and subjecting said protein to binding analysis with antibodies to said *Mycobacterium* species or antigenic portions thereof and isolating the polypeptides to which antibodies interact.
11. A method according to claim 10 wherein the *Mycobacterium* species is *M. tuberculosis*.
12. A method according to claim 10 or 11 wherein the growth medium is Lowenstein-Jensen medium.
13. A method according to claim 10 wherein the binding analysis is conducted by Western blotting and other immunoassay procedures.
14. An isolated nucleic acid molecule comprising a sequence of nucleotides encoding or complementary to a sequence encoding a polypeptide obtainable from a species of *Mycobacterium* and which polypeptide is immunointeractive with sera from a human, animal or avian species exposed to said species of *Mycobacterium* or its relative or antigenic parts thereof but which polypeptide is substantially not immunointeractive with sera from a human, animal or avian species not prior exposed to said species of *Mycobacterium* or its relative or its antigenic parts.
15. An isolated nucleic acid molecule according to claim 14 wherein the *Mycobacterium* species is *M. tuberculosis*.
16. An isolated nucleic acid molecule according to claim 15 wherein the nucleotide

sequence encodes an amino acid sequence substantially as set forth in <400>1, <400>3, <400>5, <400>7, <400>9 or an amino acid sequence having at least 60% similarity thereto.

17. An isolated nucleic acid molecule according to claim 15 wherein the nucleotide sequence is substantially as set forth in <400>1, <400>3, <400>5, <400>7, <400>9 or a nucleotide sequence having at least 60% similarity to any one of said sequences or a nucleotide sequence capable of hybridizing to any one of said sequences under low stringency conditions at 42°C.

18. An antibody specific to the polypeptide according to any one of claims 1 to 9.

19. An antibody according to claim 18 wherein the antibody is a monoclonal antibody.

20. A method for detecting the presence of *M. tuberculosis* such as in a patient suffering from tuberculosis said method comprising contacting a biological sample from a patient or subject with an antibody specific for a polypeptide from said *M. tuberculosis* and detecting a complex between said polypeptide and said antibody.

21. An assay device for *M. tuberculosis* comprising a solid support having immobilized thereon one or more polypeptides obtainable from *M. tuberculosis* or derivatives, homologues, analogues or antigenic equivalents thereof and a portion of said solid support adapted for receiving a sample from a human subject to be tested wherein said sample would contain an antibody specific for said *M. tuberculosis* polypeptide if said subject has been exposed to *M. tuberculosis* wherein upon contact between the antibody from the subject and the immobilized polypeptide, a complex forms and said complex is detected by an anti-human immunoglobulin labelled with a reporter molecule.

22. Use of a polypeptide according to any one of claims 1 to 9 in the manufacture of a medicament for the treatment of *Mycobacterium* infection in a human, animal or bird.

23. Use according to claim 22, wherein the *Mycobacterium* is *M. tuberculosis* and the infection in human.

24. A method for treating or preventing infection by *Mycobacteria* species in a human, animal or avian species said method comprising administering to said human, animal or avian species an immune response stimulating an effective amount of a polypeptide according to any one of claims 1 to 9.

25. A method according to claim 24 wherein the species of *Mycobacterium* is *M. tuberculosis* and the infection is in humans.

26. A method according to claim 24 wherein the infection is active pulmonary tuberculosis or extra-pulmonary tuberculosis.

## ABSTRACT

The present invention relates generally to molecules derived from a *Mycobacterium* species and recombinant, synthetic, derivative, homologue and analogue forms of said molecules. The molecules of the present invention are useful in diagnostic assays for *Mycobacterium* in  
5 biological and environmental samples. The present invention is particularly directed to molecules derived from *Mycobacterium tuberculosis* and related organisms and even more particularly to recombinant forms of these molecules or synthetic, derivative, homologue or analogue forms thereof and their use in diagnostic and therapeutic protocols for tuberculosis or other disease conditions associated with *M. tuberculosis* or related organisms.






Fig.1 Strategy for the isolation and expression of *M. tuberculosis* protein antigens.



(B)



(A)

Fig.2. (A) Gel purified and concentrated *M. tuberculosis* protein bands (B.1, 2, 3, 4, 5, 6, 8, 9, 10) blotted onto PVDF membrane were excised for N-terminal sequencing. (B) Concentrated *M. tuberculosis* protein bands blotted onto nitrocellulose membrane and immuno-screened using pooled normal (N) and active (A) sera respectively. Positive bands (arrows) were observed with A but not with N.

**Fig. 3** Result of homology search against the GenBank protein sequence databases. Proteins showing the highest homology to the *M. tuberculosis* protein bands are as shown.

Relative molecular weight (kDa)	Sequence from N-terminal sequencing	Match (GenBank)
B.4	SKLIEYDELALEAME	db: <sub>2</sub> SKLIEYDETARHAME <sub>16</sub> 55.74kDa, groEL1/protein cpn60 [16], pID=g44601, X60350 (80% match)
B.5	AKTIA YDEEARV	db: <sub>2</sub> AKTIA YDEEA <sub>10</sub> 56.728 kDa, CHAPERONIN2, groEL2, GenBank pID=g15000, MTTCWPA_3 (100% match)
B.6	AEVDAYKFDPDAVD	db: <sub>161</sub> AEFDAYRRDPMA <sub>172</sub> Probable exported protease, has signal sequence, very similar to three proteases / peptidases from Streptomyces, pID=e235164, MTCY427.04c (51% match)
B.9	AEYTLPLDWDY G	db: <sub>2</sub> AEYTLPLDWDY G <sub>14</sub> 23.0 kDa, superoxide dismutase, pID=g581379, MTSOD4 (100% match)
B.10	MEIDILAVAAP	db: <sub>117</sub> IEVDLLDL DAP <sub>127</sub> 33 kDa, mycocerosic acid synthase [17], pID=g149978, M95808 (56.9% match)
MMP	ATLTPVQRHDARL	db: ATLTPVQRHPRSL 14/16 kDa [18], pID=g244562, M76712






Fig. 4. Western screening of recombinant *M. tuberculosis* antigens. (A) Arrows indicate the position of the recombinant antigens on the membrane. M= Kaleidoscope protein Marker and H= strip probed with anti-RGSHis, C= a positive control of strips probed with known human serum reactive to the specific recombinant antigen. (B) Reactivity is estimated based on the intensity of band on

**Fig 5. Percentage of reactivity of recombinant TB antigens against different sera panels.** A known 38kDa antigen [20, 21] of *M. tuberculosis* was included in the screening. The gene (GeneBank Accession # M30046) for this antigen was cloned, expressed in pQE30 and partially purified as described in section E. Also shown are the percentage of reactivity of sera samples detected by a commercially available rapid TB diagnostic kit from ICT (Amrad).

Panel:	Sera	Uninfected (normal)	Active TB (Extra- Pulmonary)	Active TB (Pulmonary)	Inactive
Recombinant antigens:					
B.4		5%	55%	47.8%	22.7%
B.5		25%	35%	39.1%	27.3%
B.6		0%	5%	52.2%	9.1%
B.9		0%	25%	17.4%	18.2%
B.10		0%	5%	26.1%	0%
MMP		0%	25%	8.7%	4.5%
C17		0%	15%	13.0%	4.5%
38 kDa		0%	40%	39.1%	18.2%
ICT TB Kit		0%	55%	52.2%	13.6%

Fig 6. WESTERN SCREEN:  
DIFFERENT SERA PANELS




Fig. 7 Sensitivity: Combinations  
of rec. TB proteins






Fig. 8 Comparison of our rec. TB proteins  
with the ICT TB diagnostic kit



**Fig.9 Comparison of combinations of our rec. TB proteins with the ICT kit**



**BIRCH, STEWART, KOLASCH & BIRCH, LLP**

P.O. Box 747 • Falls Church, Virginia 22040-0747  
 Telephone: (703) 205-8000 • Facsimile: (703) 205-8050

PLEASE NOTE:  
 YOU MUST  
 COMPLETE THE  
 FOLLOWING

**COMBINED DECLARATION AND POWER OF ATTORNEY  
 FOR PATENT AND DESIGN APPLICATIONS**

As a below named inventor, I hereby declare that, my residence, post office address and citizenship are as stated next to my name; that I verily believe that I am the original, first and sole inventor (if only one inventor is named below) or an original, first and joint inventor (if plural inventors are named below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

BACTERIAL-DERIVED MOLECULES AND THERAPEUTIC AND DIAGNOSTIC USES THEREFOR

Insert Title:

Fill in Appropriate  
 Information -  
 For Use Without  
 Specification  
 Attached:

the specification of which is attached hereto. If not attached hereto,  
 the specification was filed on \_\_\_\_\_ as  
 United States Application Number \_\_\_\_\_;  
 and amended on \_\_\_\_\_ (if applicable) and/or  
 the specification was filed on \_\_\_\_\_ as PCT  
 International Application Number \_\_\_\_\_; and was  
 amended under PCT Article 19 on \_\_\_\_\_ (if applicable)

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I do not know and do not believe the same was ever known or used in the United States of America before my or our invention thereof, or patented or described in any printed publication in any country before my or our invention thereof or more than one year prior to this application, that the same was not in public use or on sale in the United States of America more than one year prior to this application, that the invention has not been patented or made the subject of an inventor's certificate issued before the date of this application in any country foreign to the United States of America on an application filed by me or my legal representative or assigns more than twelve months (six months for designs) prior to this application, and that no application for patent or inventor's certificate on this invention has been filed in any country foreign to the United States of America prior to this application by me or my legal representatives or assigns, except as follows

I hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

**Prior Foreign Application(s)**

**Priority Claimed**

Insert Priority  
 Information:  
 (if appropriate)

(Number) _____	(Country) _____	(Month/Day/Year Filed) _____	<input type="checkbox"/> Yes	<input type="checkbox"/> No
(Number) _____	(Country) _____	(Month/Day/Year Filed) _____	<input type="checkbox"/> Yes	<input type="checkbox"/> No
(Number) _____	(Country) _____	(Month/Day/Year Filed) _____	<input type="checkbox"/> Yes	<input type="checkbox"/> No
(Number) _____	(Country) _____	(Month/Day/Year Filed) _____	<input type="checkbox"/> Yes	<input type="checkbox"/> No

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional applications(s) listed below.

Insert Provisional  
 Application(s):  
 (if any)

(Application Number) _____	(Filing Date) _____
(Application Number) _____	(Filing Date) _____

All Foreign Applications, if any, for any Patent or Inventor's Certificate Filed More than 12 Months (6 Months for Designs) Prior to the Filing Date of This Application:

Country	Application Number	Date of Filing (Month/Day/Year)
_____	_____	_____
_____	_____	_____

Insert Requested  
 Information:  
 (if appropriate)

I hereby claim the benefit under Title 35, United States Code, §120 of any United States and/or PCT application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States and/or PCT application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose information which is material to the patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application

60/112,499	December 16, 1998	Pending
(Application Number)	(Filing Date)	(Status - patented, pending, abandoned)
_____	_____	_____
(Application Number)	(Filing Date)	(Status - patented, pending, abandoned)

Insert Prior U.S.  
 Application(s):  
 (if any)

I hereby appoint the following attorneys to prosecute this application and/or an international application based on this application and to transact all business in the Patent and Trademark Office connected therewith and in connection with the resulting patent based on instructions received from the entity who first sent the application papers to the attorneys identified below, unless the inventor(s) or assignee provides said attorneys with a written notice to the contrary

Raymond C. Stewart	(Reg. No. 21,066)	Terrell C. Birch	(Reg. No. 19,382)
Joseph A. Kolasch	(Reg. No. 22,463)	James M. Slattery	(Reg. No. 28,380)
Bernard L. Sweeney	(Reg. No. 24,448)	Michael K. Mutter	(Reg. No. 29,680)
Charles Gorenstein	(Reg. No. 29,271)	Gerald M. Murphy, Jr.	(Reg. No. 28,977)
Leonard R. Svensson	(Reg. No. 30,330)	Terry L. Clark	(Reg. No. 32,644)
Andrew D. Meikle	(Reg. No. 32,868)	Marc S. Weiner	(Reg. No. 32,181)
Joe McKinney Muncy	(Reg. No. 32,334)	Donald J. Daley	(Reg. No. 34,313)
John W. Bailey	(Reg. No. 32,881)	John A. Castellano	(Reg. No. 35,094)

Send Correspondence to: **BIRCH, STEWART, KOLASCH & BIRCH, LLP**

P.O. Box 747 • Falls Church, Virginia 22040-0747

Telephone: (703) 205-8000 • Facsimile: (703) 205-8050

PLEASE NOTE:  
YOU MUST  
COMPLETE  
THE  
FOLLOWING:

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon

Full Name of First  
or Sole Inventor  
Insert Name of  
Inventor  
Insert Date This  
Document is Signed

Insert Residence  
Insert Citizenship

Insert Post Office  
Address

Full Name of Second  
Inventor, if any  
sec above

Full Name of Third  
Inventor, if any  
sec above

Full Name of Fourth  
Inventor, if any  
sec above

Full Name of Fifth  
Inventor, if any  
sec above

GIVEN NAME/FAMILY NAME		INVENTOR'S SIGNATURE	DATE*
Lily CHAN		<i>Lily Chan</i>	29 Nov. 99
Residence (City, State & Country)		CITIZENSHIP	
Singapore, Singapore		Singaporean	
POST OFFICE ADDRESS (Complete Street Address including City, State & Country) c/o Bioprocessing Technology Centre, National University of Singapore 10 Kent Ridge Crescent, Singapore 110260			
GIVEN NAME/FAMILY NAME		INVENTOR'S SIGNATURE	DATE*
Maxey Ching Ming CHUNG		<i>M7 Chung</i>	29 Nov. 99
Residence (City, State & Country)		CITIZENSHIP	
Singapore, Singapore		Malaysian (Singapore P.R.)	
POST OFFICE ADDRESS (Complete Street Address including City, State & Country) c/o Bioprocessing Technology Centre, National University of Singapore 10 Kent Ridge Crescent, Singapore 110260			
GIVEN NAME/FAMILY NAME		INVENTOR'S SIGNATURE	DATE*
Renee Lay Hong LIM		<i>Renee Lay Hong</i>	29 Nov. 99
Residence (City, State & Country)		CITIZENSHIP	
Singapore, Singapore		Malaysian (Singapore P.R.)	
POST OFFICE ADDRESS (Complete Street Address including City, State & Country) c/o Bioprocessing Technology Centre, National University of Singapore 10 Kent Ridge Crescent, Singapore 110260			
GIVEN NAME/FAMILY NAME		INVENTOR'S SIGNATURE	DATE*
Residence (City, State & Country)		CITIZENSHIP	
POST OFFICE ADDRESS (Complete Street Address including City, State & Country)			
GIVEN NAME/FAMILY NAME		INVENTOR'S SIGNATURE	DATE*
Residence (City, State & Country)		CITIZENSHIP	
POST OFFICE ADDRESS (Complete Street Address including City, State & Country)			

\*DATE OF SIGNATURE